<SEC-DOCUMENT>0001104659-24-029960.txt : 20240301
<SEC-HEADER>0001104659-24-029960.hdr.sgml : 20240301
<ACCEPTANCE-DATETIME>20240301160539
ACCESSION NUMBER:		0001104659-24-029960
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240228
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240301
DATE AS OF CHANGE:		20240301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ClearPoint Neuro, Inc.
		CENTRAL INDEX KEY:			0001285550
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				582394628
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34822
		FILM NUMBER:		24709598

	BUSINESS ADDRESS:	
		STREET 1:		120 S. SIERRA AVENUE
		STREET 2:		SUITE 100
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		9499006833

	MAIL ADDRESS:	
		STREET 1:		120 S. SIERRA AVENUE
		STREET 2:		SUITE 100
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MRI INTERVENTIONS, INC.
		DATE OF NAME CHANGE:	20110714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SURGIVISION INC
		DATE OF NAME CHANGE:	20091106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SURGI VISION INC
		DATE OF NAME CHANGE:	20040331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm247180d4_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:clpt="http://clearpointneuro.com/20240228">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_clpt_clearpointneuro.com_20240228 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20240228_20240228 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_053_edei%2D%2DEntityCentralIndexKey_0001285550 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:AmendmentFlag" id="ixv-284">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityCentralIndexKey" id="ixv-285">0001285550</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="clpt-20240228.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001285550</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-28</xbrli:startDate>
        <xbrli:endDate>2024-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_906_edei--DocumentType_c20240228__20240228_zkZCLHZtFQV5"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:DocumentType" id="ixv-305">8-K</ix:nonNumeric></span> </b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 OR 15(d) of the
</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934 </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report&#160;(Date of earliest event
reported): March 1, 2024 (<span id="xdx_904_edei--DocumentPeriodEndDate_c20240228__20240228_z752lVqxUvI4"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="ixv-306">February 28, 2024</ix:nonNumeric></span>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20240228__20240228_zGgJL5U76k7a"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityRegistrantName" id="ixv-307">CLEARPOINT NEURO, INC.</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; text-align: center; width: 34%"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20240228__20240228_zMYw2MD0sbk5"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-308">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityFileNumber_c20240228__20240228_ziJyCl42LVL"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityFileNumber" id="ixv-309">001-34822</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; text-align: center; width: 33%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20240228__20240228_zML3KovuF5C8"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityTaxIdentificationNumber" id="ixv-310">58-2394628</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><b>(State or other jurisdiction</b> <b><br/>
of incorporation)</b> </td>
    <td style="text-align: center"><b>(Commission</b> <b><br/>
File Number)</b> </td>
    <td style="text-align: center"><b>(I.R.S. Employer</b> <b><br/>
Identification Number)</b> </td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20240228__20240228_zap68CALxNU8"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityAddressAddressLine1" id="ixv-311">120 S. Sierra Ave., Suite 100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240228__20240228_zJVb56f8VZae"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityAddressCityOrTown" id="ixv-312">Solana Beach</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20240228__20240228_z6aEAo2AUtY6"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityAddressStateOrProvince" id="ixv-313">CA</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20240228__20240228_zrxsglisiUgh"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:EntityAddressPostalZipCode" id="ixv-314">92075</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, zip
code) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90B_edei--CityAreaCode_c20240228__20240228_zHDn2TaqWsVk"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:CityAreaCode" id="ixv-315">888</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20240228__20240228_zRCwuWZqQiul"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:LocalPhoneNumber" id="ixv-316">287-9109</ix:nonNumeric></span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code) </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20240228__20240228_zZFJaCZ5hyzd"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:booleanfalse" name="dei:WrittenCommunications" id="ixv-317">&#168;</ix:nonNumeric></span></span>&#160;</td><td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--SolicitingMaterial_c20240228__20240228_zhdtCOyxBgbc"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:booleanfalse" name="dei:SolicitingMaterial" id="ixv-318">&#168;</ix:nonNumeric></span></span></td><td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_904_edei--PreCommencementTenderOffer_c20240228__20240228_zjyNsAyht6wd"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer" id="ixv-319">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 24.45pt"><span style="font-family: Wingdings"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20240228__20240228_z5LcvEc9iaRd"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer" id="ixv-320">&#168;</ix:nonNumeric></span></span></td><td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1pt solid; width: 41%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 26%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; width: 33%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20240228__20240228_zAhvB5bPxjsc"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:Security12bTitle" id="ixv-321">Common Stock, $0.01 par value per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20240228__20240228_z1elcTM3lra4"><ix:nonNumeric contextRef="AsOf2024-02-28" name="dei:TradingSymbol" id="ixv-322">CLPT</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt"><span id="xdx_900_edei--SecurityExchangeName_c20240228__20240228_zJ9ZcijSHYD8"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="ixv-323">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: -0.05pt">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20240228__20240228_zi8GX9zDyhUk"><ix:nonNumeric contextRef="AsOf2024-02-28" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="ixv-324">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.05pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.05pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in">Item 1.01.</td><td style="text-align: justify">Entry into a Material Definitive Agreement.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">On February&#160;28,
2024, ClearPoint Neuro, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;)
with Lake Street Capital Markets, LLC, as representative of the several underwriters named in Schedule A thereto (the &#8220;Underwriters&#8221;),
relating to the public offering of 2,307,694<b>&#160;</b>shares of common stock, par value $0.01 per share (&#8220;Common Stock&#8221;),
at a purchase price per share to the public of $6.50 (the &#8220;Offering Price&#8221;). Pursuant to the Underwriting Agreement, the Company
granted the Underwriters a&#160;30-day&#160;option to purchase up to an additional 346,154 shares of Common Stock at the Offering Price,
less any underwriting discounts and commissions, for use solely in covering any over-allotments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">Net
proceeds from the offering will be approximately $14.0 million (or approximately $16.2 million if the Underwriters exercise their
option to purchase additional shares of Common Stock in full) after deducting the underwriting discounts and commissions and other
estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for general
corporate purposes, which may include <span style="background-color: white">research and development expenditures, potential
acquisitions of or investments in businesses, products and technologies that complement the Company&#8217;s business, or repayment
of indebtedness</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">The Common Stock was
offered and sold pursuant to a preliminary prospectus supplement, dated February&#160;28, 2024, a final prospectus supplement, dated February&#160;28,
2024, and a base prospectus, dated November 20, 2023, relating to the Company&#8217;s effective shelf registration statement on Form&#160;S-3&#160;(File&#160;No.&#160;333-275476).&#160;The
Company expects the offering to close on or about March 4, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">The Underwriting Agreement
contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations
of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
other obligations of the parties and termination provisions. A copy of the Underwriting Agreement is attached as Exhibit&#160;1.1 to this
Current Report on&#160;Form&#160;8-K&#160;and&#160;is incorporated herein by reference, and the description of the Underwriting Agreement
herein is qualified in its entirety by reference to such exhibit. A copy of the opinion of Bass, Berry&#160;&amp; Sims PLC relating to
the legality of the issuance and sale of the shares of Common Stock is attached as Exhibit&#160;5.1 to this Current Report&#160;on&#160;Form&#160;8-K.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item</b> <b>9.01.</b></td><td><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><b>Exhibit&#160;No. </b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 88%"><span style="font-size: 10pt"><b>Description </b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm247180d4_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">1.1</span></a></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="tm247180d4_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Underwriting Agreement, dated as of February&#160;28, 2024, by and between ClearPoint Neuro, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named in Schedule A thereto.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm247180d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">5.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm247180d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Opinion of Bass, Berry &amp; Sims PLC regarding the legality of shares.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm247180d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">23.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm247180d4_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-size: 10pt">Consent of Bass, Berry &amp; Sims PLC (included in Exhibit 5.1).</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>104</td>
    <td>&#160;</td>
    <td>Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Date: March 1, 2024</span></td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-size: 10pt"><b>CLEARPOINT NEURO, INC.</b></span></td></tr>
  <tr>
    <td style="width: 49%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom">/s/ Danilo D&#8217;Alessandro &#160;</td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 0.1in">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Danilo D&#8217;Alessandro</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; padding-left: 0.1in">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin: 0"></p>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm247180d4_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,307,694 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CLEARPOINT NEURO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February 28, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps">Lake Street
Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">As Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">920 Second Avenue South, Suite 700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Minneapolis, Minnesota 55402</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>1.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Introductory</I></FONT>. ClearPoint Neuro, Inc., a Delaware
corporation (the &#8220;<B><I>Company</I></B>&#8221;), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters
named in <U>Schedule A</U> hereto (the &#8220;<B><I>Underwriters</I></B>,&#8221; or, each, an &#8220;<B><I>Underwriter</I></B>&#8221;),
an aggregate of 2,307,694 shares of the Company&#8217;s common stock, $0.01 par value per share (the &#8220;<B><I>Common Stock</I></B>&#8221;).
The aggregate of 2,307,694 shares so proposed to be sold is hereinafter referred to as the &#8220;<B><I>Firm Stock</I></B>.&#8221; The
Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in <U>Section 3</U> hereof, up to an additional
346,154 shares of Common Stock (the &#8220;<B><I>Optional Stock</I></B>&#8221;). The Firm Stock and the Optional Stock are hereinafter
collectively referred to as the &#8220;<B><I>Stock</I></B>.&#8221; Lake Street Capital Markets, LLC is acting as representative of the
several Underwriters and in such capacity is hereinafter referred to as the &#8220;<B><I>Representative</I></B>.&#8221;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"><I>2.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Representations and Warranties of the Company.</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT><FONT STYLE="font-variant: small-caps; color: windowtext">Representations and Warranties of the Company</FONT><FONT STYLE="color: windowtext">.
The Company represents and warrants to the several Underwriters, as of the date hereof and as of each Closing Date (as defined below),
and agrees with the several Underwriters, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT></FONT><U>Registration
Statement</U>. A registration statement of the Company on Form S&#45;3 (File No. 333&#45;275476) (including all amendments thereto,
the &#8220;<B><I>Registration Statement</I></B>&#8221;) in respect of the Stock has been filed with the Securities and Exchange
Commission (the &#8220;<B><I>Commission</I></B>&#8221;) pursuant to Rule 415 under the Securities Act of 1933, as amended (the
 &#8220;<B><I>Securities Act</I></B>&#8221;). The Company meets the requirements for use of Form S&#45;3 under the Securities Act and
the rules and regulations of the Commission thereunder (the &#8220;<B><I>Rules and Regulations</I></B>&#8221;). The Registration
Statement and any post-effective amendment thereto, each in the form heretofore delivered to you, and, excluding exhibits thereto,
to you for each of the other Underwriters, have been declared effective by the Commission in such form and conform, in all material
respects, to the requirements of the Securities Act and the Rules and Regulations. The proposed offering of the Stock may be made
pursuant to General Instruction I.B.1 of Form S-3. Other than (i) the Registration Statement, (ii) a registration statement, if any,
increasing the size of the offering filed pursuant to Rule 462(b) under the Securities Act and the Rules and Regulations (a
 &#8220;<B><I>Rule 462(b) Registration Statement</I></B>&#8221;), (iii) any Preliminary Prospectus (as defined below), (iv) the
Prospectus (as defined below) contemplated by this Agreement to be filed pursuant to Rule 424(b) of the Rules and Regulations in
accordance with <U>Section 4(i)(a)</U> hereof and (v) any Issuer Free Writing Prospectus (as defined below), no other document with
respect to the offer or sale of the Stock has heretofore been filed with the Commission. No stop order suspending the effectiveness
of the Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been
issued and no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been initiated or, to the
Company&#8217;s knowledge, threatened by the Commission (any preliminary prospectus included in the Registration Statement or filed
with the Commission pursuant to Rule 424 of the Rules and Regulations <FONT STYLE="background-color: white">that omitted the Rule
430B Information and that was used prior to the filing of the Prospectus</FONT> is hereinafter called a &#8220;<B><I>Preliminary
Prospectus</I></B>&#8221;). The Registration Statement, including all exhibits thereto and including the information contained in
the Prospectus filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations and deemed by virtue of Rules 430A,
430B and 430C under the Securities Act to be part of the Registration Statement at the time it became effective, is hereinafter
collectively called the &#8220;<B><I>Registration Statement</I></B>.&#8221; If the Company has filed a Rule 462(b) Registration
Statement, then any reference herein to the term &#8220;Registration Statement&#8221; shall be deemed to include such Rule 462
Registration Statement. The Base Prospectus (as defined below) included in the Registration Statement at the time of effectiveness
thereof, as supplemented by the final prospectus supplement relating to the offer and sale of the Stock, in the form filed pursuant
to and within the time limits described in Rule&nbsp;424(b) under the Rules and Regulations, is hereinafter called the
 &#8220;<B><I>Prospectus</I></B>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">Any reference herein
to the Registration Statement, Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated
by reference therein <FONT STYLE="background-color: white">pursuant to Item 12 of Form S-3 under the Securities Act as of the effective
date of the Registration Statement or the date of such Preliminary Prospectus or Prospectus, as the case may be</FONT>. Any reference
to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed
after the date of such Preliminary Prospectus or the Prospectus under the Securities Exchange Act of 1934, as amended (the &#8220;<B><I>Exchange
Act</I></B>&#8221;), and incorporated by reference in such Preliminary Prospectus or Prospectus, as the case may be. Any reference to
(i) the Registration Statement shall be deemed to refer to and include the annual report of the last completed fiscal year of the Company
on Form 10-K filed under Section 13(a) or 15(d) of the Exchange Act prior to the date hereof and (ii) the effective date of such Registration
Statement shall be deemed to refer to and include the date such Registration Statement became effective and, if later, the date such Form
10-K was so filed. Any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report
of the Company filed pursuant to Section 13(a) or 15(d) of the Exchange Act after the date of this Agreement that is incorporated by reference
in the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>General Disclosure Package</U>. As of the Applicable Time (as defined below) and as of the Closing Date or the Option Closing
Date (as defined below), as the case may be, neither (i) the General Use Free Writing Prospectus(es) (as defined below) issued at or prior
to the Applicable Time, the Base Prospectus and the information included on <U>Schedule C</U> hereto, all considered together (collectively,
the &#8220;<B><I>General Disclosure Package</I></B>&#8221;), nor (ii) any individual Limited Use Free Writing Prospectus (as defined below),
nor (iii) the bona fide electronic roadshow (as defined in Rule 433(h)(5) of the Rules and Regulations), when considered together with
the General Disclosure Package, included or will include any untrue statement of a material fact or omitted or will omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U>, <U>however</U>, that the Company makes no representations or warranties as to information contained in or omitted from
the Base Prospectus or any Issuer Free Writing Prospectus (as defined below), in reliance upon, and in conformity with, written information
furnished to the Company through the Representative by or on behalf of any Underwriter specifically for inclusion therein, which information
the parties hereto agree is limited to the Underwriters&#8217; Information (as defined in <U>Section 18</U>). As used in this paragraph
(b) and elsewhere in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&#8220;<B><I>Applicable
Time</I></B>&#8221; means 7:00 p.m., New York time, on February 28, 2024 or such other time as agreed to by the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&#8220;<B><I>Base
Prospectus</I></B>&#8221; means the <FONT STYLE="background-color: white">base prospectus, as amended and supplemented immediately prior
to the Applicable Time, including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&#8220;<B><I>Issuer
Free Writing Prospectus</I></B>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of the Rules and
Regulations relating to the Stock in the form filed or required to be filed with the Commission or, if not required to be filed, in the
form retained in the Company&#8217;s records pursuant to Rule 433(g) of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&#8220;<B><I>General
Use Free Writing Prospectus</I></B>&#8221; means any Issuer Free Writing Prospectus that is identified on <U>Schedule B</U> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&#8220;<B><I>Limited
Use Free Writing Prospectuses</I></B>&#8221; means any Issuer Free Writing Prospectus that is not a General Use Free Writing Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>No Stop Orders; No Material Misstatements</U>. No order preventing or suspending the use of any Preliminary Prospectus, any
Issuer Free Writing Prospectus or the Prospectus relating to the proposed offering of the Stock has been issued by the Commission, and
no proceeding for that purpose or pursuant to Section 8A of the Securities Act has been instituted or, to the Company&#8217;s knowledge,
threatened by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the
requirements of the Securities Act and the Rules and Regulations, and did not contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <U>provided</U>, <U>however</U>, that the Company makes no representations or warranties as to information
contained in or omitted from any Preliminary Prospectus, in reliance upon, and in conformity with, written information furnished to the
Company through the Representative by or on behalf of any Underwriter specifically for inclusion therein, which information the parties
hereto agree is limited to the Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Registration Statement and Prospectus Contents</U>. At the respective times, the Registration Statement and any amendments thereto
became or become effective as to the Underwriters and at each Closing Date, the Registration Statement and any amendments thereto conformed
and will conform in all material respects to the requirements of the Securities Act and the Rules and Regulations and did not and will
not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any
amendment or supplement thereto was issued and at each Closing Date, conformed and will conform in all material respects to the requirements
of the Securities Act and the Rules and Regulations and did not and will not contain an untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading; <U>provided</U>, <U>however</U>, that the foregoing representations and warranties in this paragraph (d) shall not apply to
information contained in or omitted from the Registration Statement or the Prospectus, or any amendment or supplement thereto, in reliance
upon, and in conformity with, written information furnished to the Company through the Representative by or on behalf of any Underwriter
specifically for inclusion therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>Issuer
Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and at all subsequent times through the
completion of the public offer and sale of the Stock or until any earlier date that the Company notified or notifies the
Representative as described in <U>Section 4(i)(c)</U>, did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement, Base Prospectus or the Prospectus,
including any document incorporated by reference therein and any prospectus supplement deemed to be a part thereof that has not been
superseded or modified, or included or would include an untrue statement of a material fact or omitted or would omit to state a
material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading, <U>provided</U>, <U>however</U>, that the foregoing representations and warranties in
this paragraph (e) shall not apply to information contained in or omitted from the Registration Statement or the Prospectus, or any
amendment or supplement thereto, in reliance upon, and in conformity with, written information furnished to the Company through the
Representative by or on behalf of any Underwriter specifically for inclusion therein, which information the parties hereto agree is
limited to the Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Documents Incorporated by Reference.</U> The documents incorporated by reference in the Prospectus, when they were filed with
the Commission, conformed in all material respects to the requirements of the Securities Act or the Exchange Act, as applicable, and the
rules and regulations of the Commission thereunder and none of such documents contained any untrue statement of a material fact or omitted
to state any material fact required to be stated therein, or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Prospectus, when such
documents are filed with Commission will conform in all material respects to the requirements of the Securities Act or the Exchange Act,
as applicable, and the rules and regulations of the Commission thereunder and will not contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Distribution of Offering Materials</U>. The Company has not, directly or indirectly, distributed and will not distribute any
offering material in connection with the offering and sale of the Stock other than any Preliminary Prospectus, the Prospectus and other
materials, if any, permitted under the Securities Act and consistent with <U>Section 4(i)(b)</U> below. The Company will file with the
Commission all Issuer Free Writing Prospectuses (other than a &#8220;road show&#8221; as described in Rule 433(d)(8) of the Rules and
Regulations) in the time and manner required under Rules 163(b)(2) and 433(d) of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Not an Ineligible Issuer</U>. At the time of filing the Registration Statement, any Rule 462(b) Registration Statement and any
post-effective amendments thereto, and at the date hereof, the Company was not, and the Company currently is not, an &#8220;ineligible
issuer,&#8221; as defined in Rule 405 of the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Organization and Good Standing</U>. The Company and each of its subsidiaries (as defined in <U>Section 16</U>) have been duly
organized and are validly existing as corporations or other legal entities in good standing (or the foreign equivalent thereof) under
the laws of their respective jurisdictions of organization. The Company and each of its subsidiaries are duly qualified to do business
and are in good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or lease
of property or the conduct of their respective businesses requires such qualification and have all power and authority (corporate or other)
necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure
to so qualify, be in good standing or have such power or authority would not (i) have, singularly or in the aggregate, a material adverse
effect on the business, properties, management, financial position, stockholders&#8217; equity or results of operations of the Company
and its subsidiaries taken as a whole, or (ii) impair in any material respect the ability of the Company to perform its obligations under
this Agreement or to consummate any transactions contemplated by this Agreement, the General Disclosure Package or the Prospectus (any
such effect as described in clauses (i) or (ii), a &#8220;<B><I>Material Adverse Effect</I></B>&#8221;). The subsidiaries listed in <U>Schedule
E</U> to this Agreement are the only significant subsidiaries of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Underwriting Agreement</U>. This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>The
Stock</U>. The Stock to be issued and sold by the Company to the Underwriters hereunder has been duly and validly authorized and,
when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully paid and
non-assessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the General
Disclosure Package and the Prospectus; and, except as described or incorporated by reference in the General Disclosure Package, the
issuance of the Stock is not subject to any preemptive or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Capitalization</U>. The Company has an authorized capitalization as described or incorporated by reference in the Registration
Statement, the General Disclosure Package or the Prospectus, and all of the issued shares of capital stock of the Company, including the
Stock, have been duly and validly authorized and issued, are fully paid and non-assessable, have been issued in material compliance with
federal and state securities laws, and conform in all material respects to the description thereof contained or incorporated by reference
in the General Disclosure Package and the Prospectus. All of the Company&#8217;s options, warrants and other rights to purchase or exchange
any securities for shares of the Company&#8217;s capital stock have been duly authorized and validly issued and were issued in material
compliance with federal and state securities laws. None of the outstanding shares of Common Stock were issued in violation of any preemptive
rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. As of the date set forth
in the General Disclosure Package, there were no authorized or outstanding shares of capital stock, options, warrants, preemptive rights,
rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for,
any capital stock of the Company or any of its subsidiaries other than those described above or accurately described or incorporated by
reference in the General Disclosure Package. Since the date set forth in the General Disclosure Package, the Company has not issued any
securities other than Common Stock issued pursuant to the exercise of warrants or upon the exercise of stock options or other awards outstanding
under the Company&#8217;s stock option plans, options or other securities granted or issued pursuant to the Company&#8217;s existing equity
compensation plans or other plans, and the issuance of Common Stock pursuant to employee stock purchase plans. The description of the
Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, as
described or incorporated by reference in the General Disclosure Package and the Prospectus, accurately and fairly present the information
required to be shown with respect to such plans, arrangements, options and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Capitalization of Subsidiaries</U>. All the outstanding shares of capital stock (if any) of each subsidiary of the Company have
been duly authorized and validly issued, are fully paid and nonassessable and, except to the extent set forth in the General Disclosure
Package or the Prospectus, are owned by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear
of any claim, lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>No
Conflicts</U>. The execution, delivery and performance of this Agreement by the Company, the issue and sale of the Stock by the
Company and the consummation of the transactions contemplated hereby will not (with or without notice or lapse of time or both) (i)
conflict with or result in a breach or violation of any of the terms or provisions of, constitute a default or a Debt Repayment
Triggering Event (as defined below) under, or result in the creation or imposition of any lien, encumbrance, security interest,
claim or charge upon any property or assets of the Company or any subsidiary pursuant to, any indenture, mortgage, deed of trust,
loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company
or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject,
(ii) result in any violation of the provisions of the charter or by-laws (or analogous governing instruments, as applicable) of the
Company or any of its subsidiaries or (iii) result in the violation of any law, statute, rule, regulation, judgment, order or decree
of any court or governmental or regulatory agency or body, domestic or foreign, having jurisdiction over the Company or any of its
subsidiaries or any of their properties or assets except, in the case of clauses (i) and (iii) above, for any such conflict, breach,
violation or default that would not, individually or in the aggregate, have a Material Adverse Effect. A &#8220;<B><I>Debt Repayment
Triggering Event</I></B>&#8221; means any event or condition that gives, or with the giving of notice or lapse of time would give
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder&#8217;s behalf) the right
to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company of any of its
subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>No Consents Required</U>. To the knowledge of the Company, except as may be required under the Securities Act or applicable
state securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by
the Financial Industry Regulatory Authority (&#8220;<B><I>FINRA</I></B>&#8221;) and the Nasdaq Capital Market (the &#8220;<B><I>Exchange</I></B>&#8221;)
in connection with the purchase and distribution of the Stock by the Underwriters, no consent, approval, authorization or order of, or
filing, qualification or registration (each an &#8220;<B><I>Authorization</I></B>&#8221;) with, any court, governmental or regulatory
agency or body, foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is required for the
execution, delivery and performance of this Agreement by the Company, the issuance and sale of the Stock or the consummation of the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Independent Auditors</U>. Cherry Bekaert LLP, whose report on the consolidated financial statements of the Company is filed
with the Commission as part of the Company&#8217;s most recent Annual Report on Form&nbsp;10-K and included or incorporated by reference
in the Registration Statement, the General Disclosure Package and the Prospectus, is an independent registered public accounting firm
with respect to the Company and its subsidiaries within the meaning of Article 2-01 of Regulation S-X and the Public Company Accounting
Oversight Board (United States) (the &#8220;<B><I>PCAOB</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Financial Statements</U>. The financial statements, together with the related notes, included or incorporated by reference in
the General Disclosure Package, the Prospectus and in the Registration Statement fairly present in all material respects the financial
position and the results of operations and changes in financial position of the Company and its consolidated subsidiaries at the respective
dates or for the respective periods therein specified (subject, in the case of unaudited statements, to normal year-end audit adjustments).
Such statements and related notes have been prepared in accordance with the generally accepted accounting principles in the United States
(&#8220;<B><I>GAAP</I></B>&#8221;) applied on a consistent basis throughout the periods involved, except (i)&nbsp;for such adjustments
to accounting standards and practices as are noted therein and (ii)&nbsp;in the case of unaudited interim statements, to the extent they
may exclude footnotes or may be condensed or summary statements. There are no financial statements (historical or pro forma) that are
required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated
by reference as required; the Company does not have any material liabilities or obligations, direct or contingent (including any off balance
sheet obligations), not described in the Registration Statement, and the Prospectus which are required to be described in the Registration
Statement or Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(r)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>eXtensible Business Reporting Language</U>. The interactive data in eXtensible Business Reporting Language included or incorporated
by reference in the Registration Statement fairly presents in all material respects the information called for in all material respects
and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(s)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239; </FONT><U>No
Material Adverse Change</U>. Except as otherwise stated therein, neither the Company nor any of its subsidiaries has sustained,
since the date of the latest audited financial statements included or incorporated by reference in the General Disclosure Package:
(i) any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory authority, otherwise than
as set forth or contemplated in the General Disclosure Package; (ii) any change in the capital stock of the Company (other than the
sale of shares of Common Stock as described in the Registration Statement, the General Disclosure Package and the Prospectus, the
issuance of shares of Common Stock upon exercise of stock options and warrants described as outstanding in, and the grant of options
and awards under existing equity incentive plans described in, the Registration Statement, the General Disclosure Package and the
Prospectus); (iii) any increase in the long-term debt of the Company or any of its subsidiaries, except as otherwise disclosed or
incorporated by reference in the Registration Statement, the General Disclosure Package or the Prospectus; (iv) any dividend or
distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock; or (v) any
material adverse changes, or any development involving a prospective material adverse change, in or affecting the business,
properties, assets, management, financial position, prospects, stockholders&#8217; equity or results of operations of the Company
and its subsidiaries taken as a whole, otherwise than as set forth or contemplated in the General Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(t)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Legal Proceedings</U>. <FONT STYLE="background-color: white">There are no legal or governmental proceedings (</FONT>including
any proceeding before the United States Food and Drug Administration of the U.S. Department of Health and Human Services (&#8220;<B><I>FDA</I></B>&#8221;)
or comparable federal, state, local or foreign governmental bodies (it being understood that the interaction between the Company and the
FDA and such comparable governmental bodies relating to the clinical development and product approval process shall not be deemed proceedings
for purposes of this representation)) <FONT STYLE="background-color: white">pending or, to the Company&#8217;s knowledge, threatened,
to which the Company or any subsidiary is a party or to which any of the properties of the Company or any subsidiary is subject (i)&nbsp;other
than proceedings that would not have a Material Adverse Effect on the Company and its subsidiaries, taken as a whole, or on the power
or ability of the Company to perform its obligations under this Agreement or to consummate the transactions contemplated by the Prospectus,
or (ii)&nbsp;that are required to be described in the Registration Statement or the Prospectus and are not so described. The Company is
in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business as prescribed
by the FDA, or any other federal, state or foreign agencies or bodies, except for any non-compliance that would not have a Material Adverse
Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(u)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>No Violation or Default</U>. Neither the Company nor any of its subsidiaries is (i) in violation of its charter or bylaws (or
analogous governing instrument, as applicable), (ii) in default in any respect, and no event has occurred which, with notice or lapse
of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in
any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is
bound or to which any of its property or assets is subject or (iii) in violation in any respect of any law, ordinance, governmental rule,
regulation or court order, decree or judgment to which it or its property or assets may be subject (including, without limitation, those
administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to
those performed by the FDA) except, in the case of clauses (ii) and (iii) above, for any such violation or default that would not, singularly
or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>Licenses
or Permits</U>. The Company and each of its subsidiaries possess or have obtained all licenses, certificates, authorizations and
permits issued by, and have made all declarations and filings with, the appropriate local, state, federal or foreign governmental or
regulatory agencies or bodies (including, without limitation, those administered by the FDA or by any foreign, federal, state or
local governmental or regulatory authority performing functions similar to those performed by the FDA) that are necessary for the
ownership or lease of their respective properties or the conduct of their respective businesses as described in the General
Disclosure Package and the Prospectus (collectively, the &#8220;<B><I>Governmental Permits</I></B>&#8221;), except where any
failures to possess, obtain or make the same would not, singularly or in the aggregate, have a Material Adverse Effect. Neither the
Company nor any subsidiary has received notification of any revocation, modification, suspension, termination or invalidation (or
proceedings related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental
Permit will not be renewed in the ordinary course, except where any failures to possess, obtain or make the same would not,
singularly or in the aggregate, have a Material Adverse Effect<FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(w)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Regulatory Compliance</U>.&#9;The Company has not received any unresolved FDA Form 483, notice of adverse filing, warning letter,
untitled letter or other correspondence or notice from the FDA, or any other court or arbitrator or federal, state, local, or foreign
governmental or regulatory authority, alleging or asserting noncompliance with the Federal Food, Drug and Cosmetic Act (21 U.S.C. &sect;
301 et seq.) (the &#8220;<B><I>FDCA</I></B>&#8221;). The Company and its directors, officers, employees and agents are and have been in
material compliance with applicable health care laws, including without limitation, the FDCA, the federal Anti-Kickback Statute (42 U.S.C.
 &sect; 1320a-7b(b)), the civil False Claims Act (31 U.S.C. &sect; 3729 et seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)),
the Civil Monetary Penalties Law (42 U.S.C. &sect; 1320a-7a), the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C.
 &sect; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &sect;
17921 et seq.), the exclusion laws (42 U.S.C. &sect; 1320a-7), Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX
of the Social Security Act), and the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Affordability
Reconciliation Act of 2010, including, without limitation, the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), and the regulation
promulgated pursuant to such laws, and comparable state laws, and all other local, state, federal, national, supranational, and foreign
laws, manual provisions, policies and administrative guidance relating to the regulation of the Company. The Company has not, either voluntarily
or involuntarily, initiated, conducted or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or replacement,
safety alert, post sale warning, &#8220;dear doctor&#8221; letter, or other notice or action relating to the alleged lack of safety or
efficacy of any product or any alleged product defect or violation and, to the Company&#8217;s knowledge, no third-party has initiated
or conducted any such notice or action. Neither the Company nor any of its officers, directors, employees, or agents has been or is currently
excluded from participation in the Medicare and Medicaid programs or any other state or federal health care program. To the Company&#8217;s
knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable
statutes, rules, regulations and policies of the FDA and comparable regulatory agencies outside of the United States to which the Company
is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(y)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Investment Company Act</U>. Neither the Company nor any of its subsidiaries is or, after giving effect to the offering of the
Stock and the application of the proceeds thereof as described in the General Disclosure Package and the Prospectus, will be required
to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within
the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(z)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT> <U>No Stabilization</U>. Neither the Company nor, to the Company&#8217;s knowledge, any of its officers, directors or affiliates
has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of any security of
the Company, or which caused or resulted in, or which might in the future reasonably be expected to cause or result in, stabilization
or manipulation of the price of any security of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(aa) <U>Intellectual
Property</U>. The Company and its subsidiaries own or possess the valid right to use all (i) valid and enforceable patents, patent
applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations,
copyrights, copyright registrations, licenses, trade secret rights (&#8220;<B><I>Intellectual Property Rights</I></B>&#8221;) and
(ii) inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know how, Internet
domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary
confidential information, systems, or procedures) (collectively, &#8220;<B><I>Intellectual Property Assets</I></B>&#8221;) necessary
to conduct their respective businesses as currently conducted, and as proposed to be conducted and described in the General
Disclosure Package and the Prospectus, except to the extent that the failure to own or possess adequate rights to use such
Intellectual Property Rights or Intellectual Property Assets would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect. The Company and its subsidiaries have not received any written notice of any claim that any
activities of their respective businesses infringe, misappropriate, or otherwise violate, valid and enforceable Intellectual
Property Rights of any other person, and have not received written notice of any challenge, which is to their knowledge still
pending, by any other person to the rights of the Company and its subsidiaries with respect to any Intellectual Property Rights or
Intellectual Property Assets owned or used by the Company or its subsidiaries, <FONT STYLE="background-color: white">except for any
such claim, challenge or other proceeding that would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect</FONT>. To the Company&#8217;s knowledge, the Company and its subsidiaries&#8217; respective businesses as
now conducted do not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable
Intellectual Property Rights of any other person. All licenses for the use of the Intellectual Property Rights (each an
 &#8220;<B><I>Intellectual Property License</I></B>&#8221;) necessary to conduct business as currently conducted by the Company and
described in the General Disclosure Package and the Prospectus are valid, binding upon, and enforceable by or against the parties
thereto in accordance with their respective terms. The Company has complied in all material respects with, and is not in breach nor
has received any asserted or threatened claim of breach of, any Intellectual Property License, and the Company has no knowledge of
any breach or anticipated breach by any other person to any Intellectual Property License. Except as described in the General
Disclosure Package, no claim has been made against the Company alleging the infringement by the Company of any patent, trademark,
service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person.
The Company has taken all reasonable steps designed to protect, maintain and safeguard its Intellectual Property Rights and
Intellectual Property Assets, including the execution of appropriate nondisclosure and confidentiality agreements. Except as would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the consummation of the
transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with
respect to, nor require the consent of any other person in respect of, the Company&#8217;s right to own, use, or hold for use any of
the Intellectual Property Rights as owned, used or held for use in the conduct of the business as currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(bb)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT><U>Privacy
Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable data privacy
and security laws and regulations, including, without limitation, the Health Insurance Portability and Accountability Act
(&#8220;<B><I>HIPAA</I></B>&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
Section 17921 et seq.); and to the extent applicable to the Company and its subsidiaries, the Company and its subsidiaries have
taken all necessary actions to comply with the European Union General Data Protection Regulation
(&#8220;<B><I>GDPR</I></B>&#8221;<I>)</I> (EU 2016/679) (collectively, &#8220;<B><I>Privacy Laws</I></B>&#8221;), except to the
extent that any such non-compliance with any Privacy Law would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect. To ensure compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with,
and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies and procedures
relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data (the
 &#8220;<B><I>Policies</I></B>&#8221;). The Company provides accurate notice of its Policies to its customers, employees, third party
vendors and representatives as required under applicable Privacy Laws. The Policies provide accurate and sufficient notice of the
Company&#8217;s then-current privacy practices relating to its subject matter as required under applicable Privacy Laws and such
Policies do not contain any material omissions of the Company&#8217;s then-current privacy practices. &#8220;<B><I>Personal
Data</I></B>&#8221; means (i) a natural persons&#8217; name, street address, telephone number, email address, photograph, social
security number, bank information, or customer or account number; (ii) any information which would qualify as &#8220;personally
identifying information&#8221; under the Federal Trade Commission Act, as amended; (iii) Protected Health Information as defined by
HIPAA; (iv) &#8220;personal data&#8221; as defined by GDPR; and (v) any other piece of information that allows the identification of
such natural person, or his or her family, or permits the collection or analysis of any data related to an identified person&#8217;s
health or sexual orientation. Except as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect, none of such disclosures made or contained in any of the Policies have been inaccurate, misleading, deceptive or in
violation of any Privacy Laws or Policies. Except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect, the execution, delivery and performance of this Agreement or any other agreement referred to in this
Agreement will not result in a breach of any Privacy Laws or Policies. Neither the Company nor any of its subsidiaries, (i) has
received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the Privacy
Laws, and has no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) is
currently conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any
Privacy Law; or (iii) is a party to any order, decree, or settlement agreement that imposed any material obligation or liability
under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(cc) <U>IT Systems</U>.
(i)(x)To the Company&#8217;s knowledge there has been no material security breach or attack or other compromise of or relating to any
of the Company&#8217;s and its subsidiaries&#8217; information technology and computer systems, networks, hardware, software, data (including
the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment
or technology (&#8220;<B><I>IT Systems and Data</I></B>&#8221;), and (y) the Company and its subsidiaries have not been notified of, and
have no knowledge of any event or condition that would reasonably be expected to result in any material security breach, attack or compromise
to their IT Systems and Data, (ii) except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect, the Company and its subsidiaries have complied, and are presently in compliance with, in all material respects, all applicable
laws, statutes or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority and all industry
guidelines, standards, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to
the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification and (iii) the Company and its
subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(dd)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;<U>Title
to Real and Personal Property</U>. The Company and each of its subsidiaries have good and marketable title in and (in the case of real
property) to, or have valid and marketable rights to lease or otherwise use, all items of real or personal property which are material
to the business of the Company and its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security
interests, claims and defects, except those that (i) do not, singularly or in the aggregate, materially affect the value of such property
and do not materially interfere with the use made and proposed to be made of such property by the Company or any of its subsidiaries
or (ii) would not reasonably be expected, singularly or in the aggregate, to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ee) <U>No Labor
Dispute</U>. No labor problem or dispute with the employees of the Company or any of its subsidiaries exists or, to the Company&#8217;s
knowledge, is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of
any of its or its subsidiaries&#8217; principal suppliers, contractors or customers, that could have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ff)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT><U>Compliance with ERISA</U>. To the Company&#8217;s knowledge, no &#8220;prohibited transaction&#8221; (as defined in Section
406 of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder
(&#8220;<B><I>ERISA</I></B>&#8221;), or Section 4975 of the Internal Revenue Code of 1986, as amended from time to time (the &#8220;<B><I>Code</I></B>&#8221;))
or &#8220;accumulated funding deficiency&#8221; (as defined in Section 302 of ERISA) or any of the events set forth in Section 4043(b)
of ERISA (other than events with respect to which the thirty (30)-day notice requirement under Section 4043 of ERISA has been waived)
has occurred or could reasonably be expected to occur with respect to any employee benefit plan of the Company or any of its subsidiaries
which could, singularly or in the aggregate, have a Material Adverse Effect. Each employee benefit plan of the Company or any of its subsidiaries
is in material compliance in all material respects with applicable law, including ERISA and the Code. The Company and its subsidiaries
have not incurred and could not reasonably be expected to incur material liability under Title IV of ERISA with respect to the termination
of, or withdrawal from, any pension plan (as defined in ERISA). Each pension plan for which the Company or any of its subsidiaries would
have any material liability that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred,
whether by action or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(gg)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Environmental Laws</U>. <FONT STYLE="background-color: white">The Company and each of its subsidiaries: (i)&nbsp;are in compliance
with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating to the protection
of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;<B><I>Environmental
Laws</I></B>&#8221;); (ii)&nbsp;have received and are in compliance with all permits, licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses as described in the Registration Statement and the Prospectus; and
(iii)&nbsp;have not received notice of any actual or potential liability for the investigation or remediation of any disposal or release
of hazardous or toxic substances or wastes, pollutants or contaminants, except those, in each of the cases described in clauses (i), (ii)
or (iii)&nbsp;above, for any such failure to comply or failure to receive required permits, licenses, other approvals or liability as
would not, singularly or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(hh)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> <U>Taxes</U>. The Company and its subsidiaries each (i) have timely filed all necessary federal, state, local and foreign tax
returns, and all such returns were true, complete and correct, (ii) have paid all federal, state, local and foreign taxes, for which it
is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its subsidiaries is obligated
to withhold from amounts owing to employees, creditors and third parties, and (iii) do not have any tax deficiency or claims outstanding
or assessed or, to its knowledge, proposed against any of them, except those, in each of the cases described in clauses (i), (ii) and
(iii) above, that would not, singularly or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT> <U>Insurance</U>. The Company and each of its subsidiaries carry, or are covered by, insurance in such amounts and covering such
risks as is adequate for the conduct of their respective businesses and the value of their respective properties. Neither the Company
nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would
not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received written notice from any insurer, agent
of such insurer or the broker of the Company or any of its subsidiaries that any material capital improvements or any other material expenditures
(other than premium payments) are required or necessary to be made in order to continue such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(jj)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT> <U>Accounting Controls</U>. The Company and each of its subsidiaries maintain a system of &#8220;internal control over financial
reporting&#8221; (as such term is defined in Rule 13a-15(f) of the General Rules and Regulations under the Exchange Act (the &#8220;<B><I>Exchange
Act Rules</I></B>&#8221;)) sufficient to comply with the requirements of the Exchange Act and has been designed by their respective principal
executive and principal financial officers, or under their supervision, to provide reasonable assurances that: (i) transactions are executed
in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation
of financial statements in conformity with GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in
accordance with management&#8217;s general or specific authorization; (iv) the recorded accountability for assets is compared with existing
assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) interactive data in eXtensible
Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents in all material respects
the Commission&#8217;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, in the General Disclosure
Package and in the Prospectus, the Company&#8217;s internal control over financial reporting is effective and none of the Company, its
board of directors and audit committee is aware of any &#8220;significant deficiencies&#8221; or &#8220;material weaknesses&#8221; (each
as defined by the PCAOB) in its internal control over financial reporting, or any fraud, whether or not material, that involves management
or other employees of the Company and its subsidiaries who have a significant role in the Company&#8217;s internal controls. Except as
described in the General Disclosure Package, since the end of the Company&#8217;s most recent audited fiscal year, there has been (A)
no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (B) no change in
the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect,
the Company&#8217;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(kk)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Disclosure Controls</U>. The Company and its subsidiaries maintain disclosure controls and procedures (as such is defined in
Rule 13a-15(e) of the Exchange Act Rules) that are sufficient to comply with the requirements of the Exchange Act; such disclosure controls
and procedures have been designed to ensure that information required to be disclosed by the Company and its subsidiaries in reports that
they file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s
rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s
management to allow timely decisions regarding disclosures. The Company and its subsidiaries have conducted evaluations of the effectiveness
of their disclosure controls as required by Rule 13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ll)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT><U>No Undisclosed Relationships</U>. No relationship, direct or, to the knowledge of the Company, indirect, exists between or among
the Company or any of its subsidiaries on the one hand, and the directors, officers, stockholders (or analogous interest holders), customers
or suppliers of the Company or any of its affiliates on the other hand, which is required to be described in the General Disclosure Package
and the Prospectus or a document incorporated by reference therein and which is not so described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(mm)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Registration Rights</U>. <FONT STYLE="background-color: white">Except as otherwise disclosed in the General Disclosure Package
and the Prospectus,</FONT> no person or entity has the right to require registration of shares of Common Stock or other securities of
the Company or any of its subsidiaries because of the filing or effectiveness of the Registration Statement or otherwise, except for persons
and entities who have expressly waived such right in writing or who have been given timely and proper written notice and have failed to
exercise such right within the time or times required under the terms and conditions of such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(nn)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; </FONT> <U>Margin
Rules</U>. The application of the proceeds received by the Company from the issuance, sale and delivery of the Stock as described in
the General Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the Federal
Reserve system or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(oo)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> <U>No Broker&#8217;s Fees</U>. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding
with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the
Underwriters for a brokerage commission, finder&#8217;s fee or like payment in connection with the offering and sale of the Stock or any
transaction contemplated by this Agreement, the Registration Statement, the General Disclosure Package or the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(pp)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT> <U>No Restrictions on Subsidiaries</U>. Except as described in the General Disclosure Package and the Prospectus, no subsidiary
of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject,
from paying any dividends to the Company, from making any other distribution on such subsidiary&#8217;s capital stock, from repaying to
the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or
assets to the Company or any other subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(qq)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><U>Forward-Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) contained in either the General Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(rr)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT><U>Listing</U>. The Company is subject to and in compliance in all material respects with the reporting requirements of Section
13 or Section 15(d) of the Exchange Act. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is listed on
the Exchange, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration
of the Common Stock under the Exchange Act or delisting the Common Stock from the Exchange, nor has the Company received any notification
that the Commission or FINRA is contemplating terminating such registration or listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ss)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Sarbanes-Oxley Act</U>. The Company is in material compliance with all applicable provisions of the Sarbanes-Oxley Act of 2002
and the rules and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(tt)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;
</FONT><U>No Unlawful Payments</U>. Neither the Company nor any of its subsidiaries nor, to the Company&#8217;s knowledge, any director,
officer, employee, agent, affiliate or other person acting on behalf of the Company or any subsidiary, has (i) used any corporate funds
for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, (ii) made any direct or indirect
unlawful payment to foreign or domestic government officials or employees, political parties or campaigns, political party officials,
or candidates for political office from corporate funds, (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt
Practices Act of 1977, as amended, or any applicable anti-corruption laws, rules, or regulation of any other jurisdiction in which the
Company or any subsidiary conducts business, or (iv) made any other unlawful bribe, rebate, payoff, influence payment, kickback, or other
unlawful payment to any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(uu)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;</FONT><U>Statistical
and Market Data</U>. Nothing has come to the attention of the Company that has caused the Company to believe that any third-party statistical
and market related data included in the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived
from sources that are not reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(vv)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239; </FONT><U>Compliance
with Money Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all times in
compliance with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as
amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct
Terrorism Act of 2001 (USA PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and
its subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency (collectively, the &#8220;<B><I>Anti-Money Laundering
Laws</I></B>&#8221;), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the
knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(ww)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;</FONT><U>Compliance with OFAC</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: justify">Neither the Company nor any of its subsidiaries, nor any director,
officer or employee thereof, nor, to the Company&#8217;s knowledge, any agent, affiliate, representative or other person acting on behalf
of the Company or any of its subsidiaries, is an individual or entity (&#8220;<B><I>Person</I></B>&#8221;) that is, or is owned or controlled
by a Person that is: (i) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#8217;s Office of Foreign
Assets Control (&#8220;<B><I>OFAC</I></B>&#8221;), the United Nations Security Council, the European Union (&#8220;<B><I>EU</I></B>&#8221;),
His Majesty&#8217;s Treasury, or other relevant sanctions authority (collectively, &#8220;<B><I>Sanctions</I></B>&#8221;), nor (ii) located,
organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the so-called Donetsk
People&#8217;s Republic, the so-called Luhansk People&#8217;s Republic, the Crimea Region of Ukraine, Cuba, Iran, North Korea and Syria).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">The Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other Person: (i) to fund or facilitate any activities
or business of or with any Person that, at the time of such funding or facilitation, is the subject of Sanctions, or in any country or
territory that, at the time of such funding or facilitation, is the subject of a U.S. government embargo; or (ii) in any other manner
that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter,
advisor, investor or otherwise).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(C)</TD><TD STYLE="text-align: justify">For the past five (5) years, the Company and its subsidiaries have not knowingly engaged in, are not now
knowingly engaged in, and will not engage in, any direct or indirect dealings or transactions with any Person that at the time of the
dealing or transaction is or was the subject of Sanctions or any country or territory that, at the time of the dealing or transaction
is or was the subject of Sanctions.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(xx)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Associated Persons; FINRA Matters</U>. Neither the Company nor any of its affiliates (within the meaning of FINRA Rule 5121(f)(1)) directly
or indirectly controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article
I, Section 1(ee) of the By-laws of FINRA) of, any member firm of FINRA. <FONT STYLE="background-color: white">The Company is an &#8220;experienced
issuer&#8221; within the meaning of FINRA Rule 5110(j)(6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(yy)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;</FONT><U>No
Acquisitions or Dispositions</U>. Except as are described in the Registration Statement, the General Disclosure Package and the Prospectus,
there are no contracts, letters of intent, term sheets, agreement, arrangements or understandings with respect to the direct or indirect
acquisition or disposition by the Company of material interests in real or personal property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any certificate signed by or on behalf of the
Company and delivered to the Representative or to counsel for the Underwriters shall be deemed to be a representation and warranty by
the Company to each Underwriter as to the matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>3.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Purchase, Sale and Delivery of Offered Securities</I></FONT>.
On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions herein set forth,
the Company agrees to sell to the Underwriters, and the Underwriters agree, severally and not jointly, to purchase from the Company
the respective numbers of shares of Firm Stock set forth opposite the names of the Underwriters in <U>Schedule A</U> hereto.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchase price per share
to be paid by the Underwriters to the Company for the Stock will be $6.175 per share (the &#8220;<B><I>Purchase Price</I></B>&#8221;);
provided that the Purchase Price shall be $6.50 per share with respect to shares allocated to certain investors previously identified
in writing by the Company (collectively, the &#8220;<B><I>Excluded Investors</I></B>&#8221;), such shares not to exceed 25% of the gross
proceeds of the offering of the Stock (the &#8220;<B><I>Excluded Investor Cap</I></B>&#8221;). Any proceeds received from the Excluded
Investors in excess of the Excluded Investor Cap shall be subject to the Purchase Price applicable to investors other than the Excluded
Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will deliver the
Firm Stock to the Representative for the respective accounts of the several Underwriters, through the facilities of The Depository Trust
Company, issued in such names and in such denominations as the Representative may direct by notice in writing to the Company given at
or prior to 12:00 Noon, New York time, on the second (2<SUP>nd</SUP>) full business day preceding the Closing Date against payment of
the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at a bank specified by the Company payable
to the order of the Company. Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is
a further condition of the obligations of each Underwriter hereunder. The time and date of the delivery and closing shall be at 10:00
A.M., New York time, on March 4, 2024, in accordance with Rule 15c6&#45;1 of the Exchange Act. The time and date of such payment and delivery
are herein referred to as the &#8220;<B><I>Closing Date</I></B>.&#8221; The Closing Date and the location of delivery of, and the form
of payment for, the Firm Stock may be varied by agreement between the Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Underwriters may purchase
all or less than all of the Optional Stock for use solely in covering any over-allotments made by the Underwriters in the sale and distribution
of the Firm Stock. The price per share to be paid for the Optional Stock shall be the Purchase Price. The Company agrees to sell to the
Underwriters the number of shares of Optional Stock specified in the written notice delivered by the Representative to the Company described
below and the Underwriters agree, severally and not jointly, to purchase such shares of Optional Stock. Such shares of Optional Stock
shall be purchased from the Company for the account of each Underwriter in the same proportion as the number of shares of Firm Stock set
forth opposite such Underwriter&#8217;s name on <U>Schedule A</U> bears to the total number of shares of Firm Stock (subject to adjustment
by the Representative to eliminate fractions). The option granted hereby may be exercised as to all or any part of the Optional Stock
at any time, and from time to time; <U>provided</U>, <U>however</U>, that notice of such exercise must be delivered not more than thirty
(30) days subsequent to the date of this Agreement. No Optional Stock shall be sold and delivered unless the Firm Stock previously has
been, or simultaneously is, sold and delivered. The right to purchase the Optional Stock or any portion thereof may be surrendered and
terminated at any time upon notice by the Representative to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option granted hereby
shall be exercised by written notice being given to the Company by the Representative setting forth the number of shares of the Optional
Stock to be purchased by the Underwriters and the date and time for delivery of and payment for the Optional Stock. Each date and time
for delivery of and payment for the Optional Stock (which may be the Closing Date, but not earlier) is herein called the &#8220;<B><I>Option
Closing Date</I></B>&#8221; and shall in no event be earlier than two (2) business days nor later than five (5) business days after written
notice is given. The Option Closing Date and the Closing Date are herein called the &#8220;<B><I>Closing Dates</I></B>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will deliver
the Optional Stock to the Representative for the respective accounts of the several Underwriters through the facilities of The
Depository Trust Company, issued in such names and in such denominations as the Representative may direct by notice in writing to
the Company given at or prior to 12:00 Noon, New York time, on the second (2<SUP>nd</SUP>) full business day preceding the Option
Closing Date against payment of the aggregate Purchase Price therefor by wire transfer in federal (same day) funds to an account at
a bank acceptable to the Representative payable to the order of the Company. Time shall be of the essence, and delivery at the time
and place specified pursuant to this Agreement is a further condition of the obligations of each Underwriter hereunder. The Option
Closing Date and the location of delivery of, and the form of payment for, the Optional Stock may be varied by agreement between the
Company and the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The several Underwriters propose
to offer the Stock for sale upon the terms and conditions set forth in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-variant: small-caps"><I>4.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Further Agreements of the Company. </I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT></FONT><FONT STYLE="color: windowtext">The Company agrees with the several Underwriters: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Required Filings; Amendments or Supplements; Notice to the Representative</U>. <FONT STYLE="background-color: white">During
the period beginning on the date hereof and ending on the later of the Option Closing Date or such date, as in the opinion of counsel
for the Underwriters, the Prospectus is no longer required by law to be delivered (assuming the absence of Rule 172 under the Securities
Act), in connection with sales by an Underwriter or a dealer (the&nbsp;&#8220;<B><I>Prospectus Delivery Period</I></B>&#8221;), prior
to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement), the General Disclosure Package
or the Prospectus, the Company shall furnish to the Underwriters for review a copy of each such proposed amendment or supplement, and
the Company shall not file any such proposed amendment or supplement to which the Underwriters or counsel to the Underwriters reasonably
object. Subject to this <U>Section&nbsp;4(i)(a)</U>, immediately following execution of this Agreement, the Company will prepare the Prospectus
containing the Rule 430B Information and other selling terms of the Stock, the plan of distribution thereof and such other information
as may be required by the Securities Act or the Rules and Regulations or as the Underwriters and the Company may deem appropriate, and
if requested by the Underwriters, an issuer free writing prospectus containing the selling terms of the Stock and such other information
as the Company and the Underwriters may deem appropriate, and will file or transmit for filing with the Commission, in accordance with
Rule 424(b) or Rule 433 of the Rules and Regulations, as the case may be, copies of the Prospectus and each issuer free writing prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Permitted Free Writing Prospectus</U>. The Company represents and agrees that, unless it obtains the prior consent of the Representative,
and each Underwriter represents and agrees that, unless it obtains the prior consent of the Company and the Representative, it has not
made and will not make (other than a filing pursuant to <U>Section&nbsp;4(i)(a)</U> hereof) any offer relating to the Stock that would
constitute a &#8220;free writing prospectus&#8221; as defined in Rule 405 of the Rules and Regulations unless the prior written consent
of the Representative has been received (each, a &#8220;<B><I>Permitted Free Writing Prospectus</I></B>&#8221;); <U>provided</U> that
the prior written consent of the Representative hereto shall be deemed to have been given in respect of the Issuer Free Writing Prospectuses
included in <U>Schedule B</U> hereto. The Company represents that it has treated and agrees that it will treat each Permitted Free Writing
Prospectus as an Issuer Free Writing Prospectus, comply with the requirements of Rules 164 and 433 of the Rules and Regulations applicable
to any Issuer Free Writing Prospectus, including the requirements relating to timely filing with the Commission, legending and record
keeping and will not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant
to Rule 433(d) of the Rules and Regulations a free writing prospectus prepared by or on behalf of such Underwriter that such Underwriter
otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Ongoing Compliance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="background-color: white">(A)&nbsp;During
the Prospectus Delivery Period, the Company will comply with all requirements imposed upon it by the Securities Act, as now and
hereafter amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act so far as necessary to
permit the continuance of sales of or dealings in the Stock as contemplated by the provisions hereof, the General Disclosure Package
and the Prospectus. If during such period any event occurs as a result of which the Prospectus (or if the Prospectus is not yet
available to prospective purchasers, the General Disclosure Package) would include an untrue statement </FONT>of a material fact or
omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not
misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Underwriters
or counsel to the Underwriters to amend the Registration Statement or supplement the Prospectus (or, if the Prospectus is not yet
available to prospective purchasers, the General Disclosure Package) to comply with the Securities Act or to file under the Exchange
Act any document which would be deemed to be incorporated by reference in the Prospectus (or if the Prospectus is not yet available
to prospective purchasers, the General Disclosure Package) in order to comply with the Securities Act or the Exchange Act, the
Company promptly will (x)&nbsp;notify you of such untrue statement or omission, (y)&nbsp;amend the Registration Statement or
supplement the Prospectus (or, if the Prospectus is not yet available to prospective purchasers, the General Disclosure Package) or
file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance, and
(z)&nbsp;notify you when any amendment to the Registration Statement is filed or becomes effective or when any supplement to the
Prospectus (or, if the Prospectus is not yet available to prospective purchasers, the General Disclosure Package) is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">(B) During the Prospectus
Delivery Period, if at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development
as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement, the Preliminary Prospectus or the Prospectus or included or would include, when taken together with the General Disclosure
Package, an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company (x)&nbsp;has promptly notified
or promptly will notify the Underwriters of such conflict, untrue statement or omission, (y)&nbsp;has promptly amended or will promptly
amend or supplement, at its own expense, such issuer free writing prospectus to eliminate or correct such conflict, untrue statement or
omission, and (z)&nbsp;has notified or promptly will notify you when such amendment or supplement was or is filed with the Commission
where so required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Delivery of Registration Statement</U>. To the extent not available on the Commission&#8217;s Electronic Data Gathering, Analysis
and Retrieval system or any successor system (&#8220;<B><I>EDGAR</I></B>&#8221;), upon the request of the Representative, to furnish promptly
to the Representative and to counsel for the Underwriters a signed copy of the Registration Statement as originally filed with the Commission,
and of each amendment thereto filed with the Commission, including all consents and exhibits filed therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Delivery of Copies</U>. Upon request of the Representative, to the extent not available on EDGAR, to deliver promptly to the
Representative in New York City such number of the following documents as the Representative shall reasonably request: (i) conformed copies
of the Registration Statement as originally filed with the Commission (in each case excluding exhibits), (ii) each Preliminary Prospectus,
(iii) any Issuer Free Writing Prospectus, (iv) the Prospectus (the delivery of the documents referred to in clauses (i), (ii), (iii) and
(iv) of this paragraph (e) to be made not later than 10:00 A.M., New York time, on the business day following the execution and delivery
of this Agreement), (v) conformed copies of any amendment to the Registration Statement (excluding exhibits), (vi) any amendment or supplement
to the General Disclosure Package or the Prospectus (the delivery of the documents referred to in clauses (v) and (vi) of this paragraph
(e) to be made not later than 10:00 A.M., New York City time, on the business day following the date of such amendment or supplement),
and (vii) any document incorporated by reference in the General Disclosure Package or the Prospectus (excluding exhibits thereto) (the
delivery of the documents referred to in clause (vi) of this paragraph (e) to be made not later than 10:00 A.M., New York City time, on
the business day following the date of such document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT> <U>Earnings Statement</U>. To make generally available (which may be satisfied by filing with the Commission&#8217;s EDGAR system)
to its stockholders as soon as practicable, but in any event not later than fifteen (15) months after the effective date of the Registration
Statement (as defined in Rule 158(c) of the Rules and Regulations), an earnings statement of the Company and its subsidiaries (which need
not be audited) complying with Section 11(a) of the Securities Act (including, at the option of the Company, Rule 158).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Blue Sky Compliance</U>. To take promptly from time to time such actions as the Representative may reasonably request to qualify
the Stock for offering and sale under the securities or Blue Sky laws of such jurisdictions (domestic or foreign) as the Representative
may reasonably designate and to continue such qualifications in effect, and to comply with such laws, for so long as required to permit
the offer and sale of Stock in such jurisdictions; <U>provided</U> that the Company and its subsidiaries shall not be obligated to (i)
qualify as foreign corporations in any jurisdiction in which they are not so qualified, (ii) file a general consent to service of process
in any jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Reports</U>. Upon request, during the period of two (2) years from the date hereof, to deliver to each of the Underwriters,
(i) as soon as they are available, copies of all reports or other communications (financial or other) furnished to stockholders, and (ii)
as soon as they are available, copies of any reports and financial statements furnished or filed with the Commission or any national securities
exchange on which the Common Stock is listed. However, so long as the Company is subject to the reporting requirements of either Section
13 or Section 15(d) of the Exchange Act and is timely filing reports with the Commission on EDGAR, it is not required to furnish such
reports or statements to the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239; </FONT><U>Lock-Up</U>.
During the period commencing on and including the date hereof and ending on and including the ninetieth (90th) day following the
date of this Agreement (the &#8220;<B><I>Lock-Up Period</I></B>&#8221;), the Company will not, without the prior written consent of
the Representative, directly or indirectly offer, sell (including, without limitation, any short sale), assign, transfer, pledge,
contract to sell, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-1(h) under the Exchange
Act, or otherwise dispose of, or announce the offering of, or submit or file any registration statement under the Securities Act in
respect of, any Common Stock, options, rights or warrants to acquire Common Stock or securities exchangeable or exercisable for or
convertible into Common Stock (other than is contemplated by this Agreement with respect to the Stock) or publicly announce any
intention to do any of the foregoing; <U>provided</U>, <U>however</U>, that the Company may: (i) issue Common Stock and options to
purchase Common Stock, shares of Common Stock underlying options granted and other securities, each pursuant to any director or
employee stock option plan, stock ownership plan or dividend reinvestment plan of the Company in effect on the date hereof and
described in the General Disclosure Package; (ii) issue Common Stock pursuant to the conversion of securities, which securities are
outstanding on the date hereof and described in the General Disclosure Package; (iii) sell or issue, or enter into an agreement to
sell or issue, Common Stock or securities convertible into or exercisable or exchangeable for Common Stock in connection with (1)
mergers, (2) acquisition of securities, businesses, property or other assets, (3) joint ventures or (4) strategic alliances; <U>provided</U>
that each recipient of Common Stock or securities convertible into or exercisable for Common Stock pursuant to this clause (iii)
shall execute a &#8220;lock-up agreement&#8221; substantially in the form of <U>Exhibit I</U> hereto; or (iv) adopt a new equity
incentive plan, and file a registration statement on Form S-8 under the Securities Act to register the offer and sale of securities
to be issued pursuant to such new equity incentive plan, and issue securities pursuant to such new equity incentive plan (including,
without limitation, the issuance of shares of Common Stock upon the exercise of options or other securities issued pursuant to such
new equity incentive plan), <U>provided</U> that (1) such new equity incentive plan satisfies the transaction requirements of
General Instruction A.1 of Form S-8 under the Securities Act and (2) this clause (iv) shall not be available unless each recipient
set forth on <U>Schedule </U>D of shares of Common Stock, or securities exchangeable or exercisable for or convertible into Common
Stock, pursuant to such new equity incentive plan shall be contractually prohibited from selling, offering, disposing of or
otherwise transferring any such shares or securities during the remainder of the Lock-Up Period. <FONT STYLE="font-size: 10pt">The
Company will cause each person and entity listed in <U>Schedule D</U> to furnish to the Representative, prior to the Closing Date, a
 &#8220;lock-up&#8221; agreement, substantially in the form of <U>Exhibit I</U> hereto. In addition, the Company will direct the
transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such
 &#8220;lock-up&#8221; agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Delivery of SEC Correspondence</U>. During the Prospectus Delivery Period, to supply the Underwriters with copies of all correspondence
to and from, and all documents issued to and by, the Commission in connection with the registration of the Stock under the Securities
Act or any of the Registration Statement, any Preliminary Prospectus or the Prospectus, or any amendment or supplement thereto or document
incorporated by reference therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Press Releases</U>. Prior to the Closing Date, not to issue any press release or other communication directly or indirectly
or hold any press conference with respect to the Company, its condition, financial or otherwise, or earnings, business affairs or business
prospects (except for routine oral marketing communications in the ordinary course of business and consistent with the past practices
of the Company and of which the Representative is notified), without the prior consent of the Representative (which consent shall not
be unreasonably withheld), unless in the judgment of the Company and its counsel, and after notification to the Representative, such press
release or communication is required by law or applicable Exchange rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Compliance with Regulation M</U>. Until the Underwriters shall have notified the Company of the completion of the resale of
the Stock, that the Company will not, and will use its reasonable best efforts to cause its affiliated purchasers (as defined in Regulation
M under the Exchange Act) not to, either alone or with one or more other persons, bid for or purchase, for any account in which it or
any of its affiliated purchasers has a beneficial interest, any Stock, or attempt to induce any person to purchase any Stock; and not
to, and to use its reasonable best efforts to cause its affiliated purchasers not to, make bids or purchase for the purpose of creating
actual, or apparent, active trading in or of raising the price of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Registrar and Transfer Agent</U>. To maintain, at its expense, a registrar and transfer agent for the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Use of Proceeds</U>. To apply the net proceeds from the sale of the Stock as set forth in the Registration Statement, the General
Disclosure Package and the Prospectus under the heading &#8220;Use of Proceeds,&#8221; and except as disclosed in the General Disclosure
Package, the Company does not intend to use any of the proceeds from the sale of the Stock hereunder to repay any outstanding debt owed
to any affiliate of any Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Exchange Listing</U>. To use its reasonable best efforts to list, subject to notice of issuance, the Stock on the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Performance of Covenants and Satisfaction of Conditions</U>. To use its reasonable best efforts to do and perform all things
required to be done or performed under this Agreement by the Company prior to each Closing Date and to satisfy all conditions precedent
to the delivery of the Firm Stock and the Optional Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>5.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Payment of Expenses</I></FONT>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT>The
Company agrees to pay, or reimburse if paid by any Underwriter, whether or not the transactions contemplated hereby are consummated
or this Agreement is terminated: (a) the costs incident to the authorization, issuance, sale, preparation and delivery of the Stock
and any taxes payable in that connection; (b) the costs incident to the preparation, printing and distribution of the Registration
Statement, the Base Prospectus, any Preliminary Prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package, the
Prospectus, any amendments, supplements and exhibits thereto or any document incorporated by reference therein and the costs of
printing, reproducing and distributing, the &#8220;Agreement Among Underwriters&#8221; between the Representative and the
Underwriters, the Master Selected Dealers&#8217; Agreement, the Underwriters&#8217; Questionnaire, this Agreement and any closing
documents by mail, telex or other means of communications; (c) the reasonable and documented fees and expenses (including related
fees and expenses of counsel for the Underwriters) incurred in connection with securing any required review by FINRA of the terms of
the sale of the Stock and any filings made with FINRA; (d) any applicable Exchange listing or other fees; (e) the reasonable fees
and expenses (including related fees and expenses of counsel to the Underwriters) of qualifying the Stock under the securities laws
of the several jurisdictions as provided in <U>Section 4(i)(g) </U>and of preparing, printing and distributing wrappers, Blue Sky
Memoranda and Legal Investment Surveys; (f) all fees and expenses of the registrar and transfer agent of the Stock; (g) the costs
and expenses relating to investor presentations on any &#8220;road show&#8221; undertaken in connection with the marketing of the
offering of the Stock, including, without limitation, expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in
connection with the road show presentations with the prior approval of the Company; and (h) all other costs and expenses incident to
the offering of the Stock or the performance of the obligations of the Company under this Agreement (including, without limitation,
the fees and expenses of the Company&#8217;s counsel and the Company&#8217;s independent accountants); <U>provided</U> that, except
to the extent otherwise provided in this <U>Section <FONT STYLE="font-size: 10pt">5 </FONT></U><FONT STYLE="font-size: 10pt">and in <U>Sections
9</U> and <U>10</U>, the Underwriters shall pay their own costs and expenses, including the fees and expenses of their counsel not
contemplated herein, any transfer taxes on the resale of any Stock by them and the expenses of advertising any offering of the Stock
made by the Underwriters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT>Inclusive of the expenses set forth in <U>Section 5(a)</U> above, the Company agrees to reimburse the Representative for its reasonable
out-of-pocket expenses in connection with the performance of its activities under this Agreement, including fees and expenses of the Underwriters&#8217;
outside legal counsel, such reimbursement not to exceed $90,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>6.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Conditions of Underwriters&#8217; Obligations.</I></FONT> The
respective obligations of the several Underwriters hereunder are subject to the accuracy, when made and as of the Applicable Time and
on such Closing Date, of the representations and warranties of the Company contained herein, to the accuracy of the statements of the
Company made in any certificates pursuant to the provisions hereof, to the performance by the Company of its obligations hereunder, and
to each of the following additional terms and conditions:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Registration Compliance; No Stop Orders</U>. The Registration Statement shall remain effective, and no stop order suspending
the effectiveness of the Registration Statement or any part thereof, preventing or suspending the use of any Base Prospectus, any Preliminary
Prospectus, the Prospectus or any Permitted Free Writing Prospectus or any part thereof shall have been issued and no proceedings for
that purpose or pursuant to Section 8A under the Securities Act shall have been initiated or, to the Company&#8217;s knowledge, threatened
by the Commission, and all requests for additional information on the part of the Commission (to be included or incorporated by reference
in the Registration Statement or the Prospectus or otherwise) shall have been complied with to the reasonable satisfaction of the Representative;
the Rule 462(b) Registration Statement, if any, each Issuer Free Writing Prospectus and the Prospectus shall have been filed with, the
Commission within the applicable time period prescribed for such filing by, and in compliance with, the Rules and Regulations and in accordance
with <U>Section 4(i)(a)</U>, and the Rule 462(b) Registration Statement, if any, shall have become effective immediately upon its filing
with the Commission; and FINRA shall have raised no unresolved objection to the fairness and reasonableness of the terms of this Agreement
or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT> <U>No Material Misstatements</U>. None of the Underwriters shall have discovered and disclosed to the Company on or prior to such
Closing Date that the Registration Statement or any amendment or supplement thereto contains an untrue statement of a fact which, in the
opinion of counsel for the Underwriters, is material or omits to state any fact which, in the opinion of such counsel, is material and
is required to be stated therein or is necessary to make the statements therein not misleading, or that the General Disclosure Package,
any Issuer Free Writing Prospectus or the Prospectus or any amendment or supplement thereto contains an untrue statement of fact which,
in the opinion of such counsel, is material or omits to state any fact which, in the opinion of such counsel, is material and is necessary
in order to make the statements, in the light of the circumstances in which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Corporate Proceedings</U>. All corporate proceedings incident to the authorization, form and validity of each of this Agreement,
the Stock, the Registration Statement, the General Disclosure Package, each Issuer Free Writing Prospectus and the Prospectus and the
transactions contemplated hereby shall be reasonably satisfactory in all material respects to counsel for the Underwriters, and the Company
shall have furnished to such counsel all documents and information that they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Opinion and 10b-5 Statement of Counsel for the Company</U><I>. </I>Bass, Berry &amp; Sims PLC shall have furnished to the Representative
such counsel&#8217;s written opinion and 10b-5 Statement, as counsel to the Company, addressed to the Underwriters and dated such Closing
Date, in form previously agreed to with the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Opinion and 10b-5 Statement of Counsel for the Underwriters.</U> The Representative shall have received from Nelson Mullins
Riley &amp; Scarborough LLP, counsel for the Underwriters, such opinion or opinions and 10b-5 Statement, dated such Closing Date, with
respect to such matters as the Underwriters may reasonably require, and the Company shall have furnished to such counsel such documents
as they may reasonably request for enabling them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Comfort Letter</U>. At the time of the execution of this Agreement, the Representative shall have received from Cherry Bekaert
LLP a letter, addressed to the Underwriters, executed and dated such date, in form and substance satisfactory to the Representative (i)
confirming that it is an independent registered accounting firm with respect to the Company and its consolidated subsidiaries within the
meaning of the Securities Act and the Rules and Regulations and PCAOB and (ii) stating the conclusions and findings of the firm, of the
type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters, with respect to the financial statements
and certain financial information contained or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Bring Down Comfort</U>. On the effective date of any post-effective amendment to the Registration Statement and on such Closing
Date, the Representative shall have received a letter (the &#8220;<B><I>bring-down letter</I></B>&#8221;) from Cherry Bekaert LLP addressed
to the Underwriters and dated such Closing Date confirming, as of the date of the bring-down letter (or, with respect to matters involving
changes or developments since the respective dates as of which specified financial information is given in the General Disclosure Package
and the Prospectus, as the case may be, as of a date not more than three (3) business days prior to the date of the bring-down letter),
the conclusions and findings of the firm, of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters,
with respect to the financial information and other matters covered by its letter delivered to the Representative concurrently with the
execution of this Agreement pursuant to paragraph (g) of this <U>Section 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>Officer&#8217;s
Certificate</U>. The Company shall have furnished to the Representative a certificate, dated such Closing Date, of its Chief
Executive Officer or President and its Chief Financial Officer stating in their respective capacities as officers of the Company on
behalf of the Company that (i) no stop order suspending the effectiveness of the Registration Statement (including, for avoidance of
doubt, any Rule 462(b) Registration Statement), or any post-effective amendment thereto, shall be in effect and no proceedings for
such purpose shall have been instituted or, to their knowledge, threatened by the Commission, (ii) for the period from and including
the date of this Agreement through and including such Closing Date, there has not occurred any Material Adverse Effect, (iii) to
their knowledge, as of such Closing Date, the representations and warranties of the Company in this Agreement are true and correct
(except to the extent that such representations and warranties speak as of another date, in which case such representations and
warranties shall be true and correct as of such other date), and the Company has complied with all agreements and satisfied all
conditions on its part to be performed or satisfied hereunder at or prior to such Closing Date, and (iv) there has not been,
subsequent to the date of the most recent audited financial statements included or incorporated by reference in the General
Disclosure Package, any Material Adverse Effect, or any change or development that, singularly or in the aggregate, would reasonably
be expected to have a Material Adverse Effect<FONT STYLE="font-size: 10pt">, except as set forth in the General Disclosure Package
and the Prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Material Adverse Effect</U>. Since the date of the latest audited financial statements included in the General Disclosure
Package or incorporated by reference in the General Disclosure Package as of the date hereof, (i) neither the Company nor any of its subsidiaries
shall have sustained any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered
by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth in the General Disclosure
Package, and (ii) there shall not have been any change in the capital stock or long-term debt of the Company or any of its subsidiaries,
or any change, or any development involving a prospective change, in or affecting the business, properties, management, financial position,
stockholders&#8217; equity or results of operations of the Company and its subsidiaries, otherwise than as set forth in the General Disclosure
Package, the effect of which, in any such case described in clause (i) or (ii) of this paragraph (i), is, in the reasonable judgment of
the Representative, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or delivery of the Stock
on the terms and in the manner contemplated in the General Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>No Legal Impediment to Issuance</U>. No action shall have been taken and no law, statute, rule, regulation or order shall have
been enacted, adopted or issued by any governmental or regulatory agency or body which would prevent the issuance or sale of the Stock;
and no injunction, restraining order or order of any other nature by any federal or state court of competent jurisdiction shall have been
issued which would prevent the issuance or sale of the Stock or materially and adversely affect or potentially materially and adversely
affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>Market
Conditions</U>. Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following: (i)
trading in any of the Company&#8217;s securities shall have been suspended or materially limited by the Commission or the Exchange,
or trading in securities generally on the New York Stock Exchange, Nasdaq Global Select Market, Nasdaq Global Market, Nasdaq Capital
Market or the NYSE American or in the over-the-counter market, or trading in any securities of the Company on any exchange or in the
over-the-counter market, shall have been suspended or materially limited, or minimum or maximum prices or maximum range for prices
shall have been established on any such exchange or such market by the Commission, by such exchange or market or by any other
regulatory body or governmental authority having jurisdiction, (ii) a banking moratorium shall have been declared by Federal or
state authorities or a material disruption has occurred in commercial banking or securities settlement or clearance services in the
United States, (iii) the United States shall have become engaged in hostilities, or the subject of an act of terrorism, or there
shall have been an outbreak of or escalation in hostilities involving the United States, or there shall have been a declaration of a
national emergency or war by the United States or (iv) there shall have occurred such a material adverse change in general economic,
political or financial conditions (or the effect of international conditions on the financial markets in the United States shall be
such) as to make it, in the reasonable judgment of the Representative, impracticable or inadvisable to proceed with the sale or
delivery of the Stock on the terms and in the manner contemplated in the General Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;
</FONT><U>Exchange Listing</U>. The Company shall have filed a Notification: Listing of Additional Shares with the Exchange, and the shares
of Stock to be delivered on the Closing Date or the Option Closing Date (as applicable), will be approved for listing on the Exchange,
subject to official notice of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;
</FONT><U>Good Standing</U>. The Representative shall have received on and as of such Closing Date satisfactory evidence of the good standing
of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such
other jurisdictions as the Representative may reasonably request, in each case in writing or any standard form of telecommunication from
the appropriate governmental authorities of such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Lock-Up Agreements</U>. The Representative shall have received the written agreements, substantially in the form of <U>Exhibit&nbsp;I</U>
hereto, of the officers and directors of the Company listed in <U>Schedule D</U> to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Secretary&#8217;s Certificate</U>. The Company shall have furnished to the Representative a Secretary&#8217;s Certificate of
the Company, in form and substance reasonably satisfactory to counsel for the Underwriters and customary for the type of offering contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Chief Financial Officer Certificate</U>. The Company shall have furnished to the Representative a certificate, dated such Closing
Date, of its Chief Financial Officer, in form and substance reasonably satisfactory to the Representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Additional Documents</U>. On or prior to such Closing Date, the Company shall have furnished to the Representative such further
certificates and documents as the Representative may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All opinions, letters, evidence
and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if
they are in form and substance reasonably satisfactory to counsel for the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-variant: small-caps"><I>7.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Indemnification and Contribution.</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT><U>Indemnification
of Underwriters by the Company</U>. The Company shall indemnify and hold harmless each Underwriter, its affiliates, directors,
officers, managers, members, employees, representatives and agents and each person, if any, who controls any Underwriter within the
meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;<B><I>Underwriter Indemnified
Parties</I></B>,&#8221; and each an &#8220;<B><I>Underwriter Indemnified Party</I></B>&#8221;) against any loss, claim, damage,
expense or liability whatsoever (or any action, investigation or proceeding in respect thereof), joint or several, to which such
Underwriter Indemnified Party may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage,
expense, liability, action, investigation or proceeding arises out of or is based upon (A) any untrue statement or alleged untrue
statement of a material fact contained in any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer
information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration Statement,
the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, or in any materials or
information provided to investors by, or with the approval of, the Company in connection with the marketing of the offering of the
Stock, including any roadshow or investor presentations made to investors by the Company (whether in person or electronically)
(&#8220;<B><I>Marketing Materials</I></B>&#8221;) or (B) the omission or alleged omission to state in any Preliminary Prospectus,
any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) of
the Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document
incorporated by reference therein, or in any Marketing Materials, a material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances in which they were made, not misleading, and shall reimburse each
Underwriter Indemnified Party promptly upon demand for any legal fees or other expenses reasonably incurred by that Underwriter
Indemnified Party in connection with investigating, or preparing to defend, or defending against, or appearing as a third party
witness in respect of, or otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action,
investigation or proceeding, as such fees and expenses are incurred; <U>provided</U>, <U>however</U>, that the Company shall not be
liable in any such case to the extent that any such loss, claim, damage, expense or liability arises out of or is based upon an
untrue statement or alleged untrue statement in, or omission or alleged omission from any Preliminary Prospectus, the Registration
Statement or the Prospectus, or any such amendment or supplement thereto, any Issuer Free Writing Prospectus or any Marketing
Materials made in reliance upon and in conformity with written information furnished to the Company through the Representative by or
on behalf of any Underwriter specifically for use therein, which information the parties hereto agree is limited to the
Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">The indemnity agreement in this <U>Section
7(a)</U> is not exclusive and is in addition to each other liability which the Company might have under this Agreement or otherwise, and
shall not limit any rights or remedies which may otherwise be available under this Agreement, at law or in equity to any Underwriter Indemnified
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT><U>Indemnification of Company by the Underwriters</U>. Each Underwriter, severally and not jointly, shall indemnify and hold harmless
the Company and its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within
the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;<B><I>Company Indemnified Parties</I></B>&#8221;
and each a &#8220;<B><I>Company Indemnified Party</I></B>&#8221;) against any loss, claim, damage, expense or liability whatsoever (or
any action, investigation or proceeding in respect thereof), joint or several, to which such Company Indemnified Party may become subject,
under the Securities Act or otherwise, insofar as such loss, claim, damage, expense, liability, action, investigation or proceeding arises
out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in any Preliminary Prospectus,
any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) of the
Rules and Regulations, the Registration Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated
by reference therein, or (ii) the omission or alleged omission to state in any Preliminary Prospectus, any Issuer Free Writing Prospectus,
any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) of the Rules and Regulations, the Registration
Statement or the Prospectus, or in any amendment or supplement thereto or document incorporated by reference therein, a material fact
required to be stated therein or necessary to make the statements therein, in the light of the circumstances in which they were made,
not misleading, but in each case only to the extent that the untrue statement or alleged untrue statement or omission or alleged omission
was made in reliance upon and in conformity with written information furnished to the Company through the Representative by or on behalf
of that Underwriter specifically for use therein, which information the parties hereto agree is limited to the Underwriters&#8217; Information,
and shall reimburse the Company Indemnified Parties for any legal or other expenses reasonably incurred by such party in connection with
investigating or preparing to defend or defending against or appearing as third party witness in connection with any such loss, claim,
damage, liability, action, investigation or proceeding, as such fees and expenses are incurred. This indemnity agreement is not exclusive
and will be in addition to any liability which the Underwriters might otherwise have and shall not limit any rights or remedies which
may otherwise be available under this Agreement, at law or in equity to the Company Indemnified Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT>Promptly
after receipt by an indemnified party under this <U>Section 7</U> of notice of the commencement of any action, the indemnified party
shall, if a claim in respect thereof is to be made against an indemnifying party under this <U>Section <FONT STYLE="font-size: 10pt">7</FONT></U><FONT STYLE="font-size: 10pt">,
notify such indemnifying party in writing of the commencement of that action; <U>provided</U>, <U>however</U><I>,</I> that the
failure to notify the indemnifying party shall not relieve it from any liability which it may have under this <U>Section 7</U>
except to the extent it has been materially prejudiced by such failure; and, <U>provided</U>, <U>further</U><I>,</I> that the
failure to notify an indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise
than under this <U>Section 7</U>. If any such action shall be brought against an indemnified party, and it shall notify the
indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes,
jointly with any other similarly notified indemnifying party, to assume the defense of such action with counsel reasonably
satisfactory to the indemnified party (which counsel shall not, except with the written consent of the indemnified party, be counsel
to the indemnifying party). After notice from the indemnifying party to the indemnified party of its election to assume the defense
of such action, except as provided herein, the indemnifying party shall not be liable to the indemnified party under <U>Section
7</U> for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense of such action
other than reasonable costs of investigation; <U>provided</U>, <U>however</U><I>,</I> that any indemnified party shall have the
right to employ separate counsel in any such action and to participate in the defense of such action but the fees and expenses of
such counsel (other than reasonable costs of investigation) shall be at the expense of such indemnified party unless (i) the
employment thereof has been specifically authorized in writing by the Company in the case of a claim for indemnification under <U>Section
7(a)</U> or the Representative in the case of a claim for indemnification under <U>Section 7(b)</U>, (ii) such indemnified party
shall have been advised by its counsel that there may be one or more legal defenses available to it which are different from or
additional to those available to the indemnifying party, (iii) the indemnifying party has failed to assume the defense of such
action and employ counsel reasonably satisfactory to the indemnified party within a reasonable period of time after notice of the
commencement of the action or the indemnifying party does not diligently defend the action after assumption of the defense, in which
case, if such indemnified party notifies the indemnifying party in writing that it elects to employ separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to assume the defense of (or, in the case of a failure to
diligently defend the action after assumption of the defense, to continue to defend) such action on behalf of such indemnified party
and the indemnifying party shall be responsible for legal or other expenses subsequently incurred by such indemnified party in
connection with the defense of such action; <U>provided</U>, <U>however</U>, that the indemnifying party shall not, in connection
with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same
general allegations or circumstances, be liable for the reasonable fees and expenses of more than one separate firm of attorneys at
any time for all such indemnified parties (in addition to any local counsel), which firm shall be designated in writing by the
Representative if the indemnified parties under this <U>Section 7</U> consist of any Underwriter Indemnified Party or by the Company
if the indemnified parties under this <U>Section&nbsp;7</U> consist of any Company Indemnified Parties. Subject to this <U>Section
7(c)</U>, the amount payable by an indemnifying party under <U>Section 7</U> shall include, but not be limited to, (x) reasonable
legal fees and expenses of counsel to the indemnified party and any other expenses in investigating, or preparing to defend or
defending against, or appearing as a third party witness in respect of, or otherwise incurred in connection with, any action,
investigation, proceeding or claim, and (y) all amounts paid in settlement of any of the foregoing. No indemnifying party shall,
without the prior written consent of the indemnified parties (which consent shall not be unreasonably withheld or delayed), settle
or compromise or consent to the entry of judgment with respect to any pending or threatened action or any claim whatsoever, in
respect of which indemnification or contribution could be sought under this <U>Section 7</U> (whether or not the indemnified parties
are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of
each indemnified party in form </FONT>and substance reasonably satisfactory to such indemnified party from all liability arising out
of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or
on behalf of any indemnified party. Subject to the provisions of the following sentence, no indemnifying party shall be liable for
settlement of any pending or threatened action or any claim whatsoever that is effected without its written consent (which consent
shall not be unreasonably withheld or delayed), but if settled with its written consent, if its consent has been unreasonably
withheld or delayed or if there be a judgment for the plaintiff in any such matter, the indemnifying party agrees to indemnify and
hold harmless any indemnified party from and against any loss or liability by reason of such settlement or judgment. In addition, if
at any time an indemnified party shall have requested that an indemnifying party reimburse the indemnified party for fees and
expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature contemplated by <U>Section
7<FONT STYLE="font-size: 10pt">(a)</FONT></U><FONT STYLE="font-size: 10pt"> or <U>7(b)</U> effected without its written consent if
(i) such settlement is entered into more than forty-five (45) days after receipt by such indemnifying party of the request for
reimbursement, (ii) such indemnifying party shall have received notice of the terms of such settlement at least thirty (30) days
prior to such settlement being entered into and (iii)&nbsp;such indemnifying party shall not have reimbursed such indemnified party
in accordance with such request prior to the date of such settlement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT>If the indemnification provided for in this <U>Section 7</U> is unavailable or insufficient to hold harmless an indemnified party
under <U>Section 7(a)</U> or <U>7(b)</U>, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute
to the amount paid, payable or otherwise incurred by such indemnified party as a result of such loss, claim, damage, expense or liability
(or any action, investigation or proceeding in respect thereof), as incurred, (i) in such proportion as shall be appropriate to reflect
the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Stock, or (ii)
if the allocation provided by clause (i) of this <U>Section 7(d)</U> is not permitted by applicable law, in such proportion as is appropriate
to reflect not only the relative benefits referred to in clause (i) of this <U>Section 7(d)</U> but also the relative fault of the Company,
on the one hand and the Underwriters on the other with respect to the statements, omissions, acts or failures to act which resulted in
such loss, claim, damage, expense or liability (or any action, investigation or proceeding in respect thereof) as well as any other relevant
equitable considerations. The relative benefits received by the Company, on the one hand and the Underwriters on the other with respect
to such offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Stock purchased under
this Agreement (before deducting expenses) received by the Company, bear to the total underwriting discounts and commissions received
by the Underwriters with respect to the Stock purchased under this Agreement, in each case as set forth in the table on the cover page
of the Prospectus. The relative fault of the Company on the one hand and the Underwriters on the other shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state
a material fact relates to information supplied by the Company, on the one hand or the Underwriters on the other, the intent of the parties
and their relative knowledge, access to information and opportunity to correct or prevent such untrue statement, omission, act or failure
to act; <U>provided</U> that the parties hereto agree that the written information furnished to the Company through the Representative
by or on behalf of the Underwriters for use in the Preliminary Prospectus, the Registration Statement or the Prospectus, or in any amendment
or supplement thereto or document incorporated by reference therein, consists solely of the Underwriters&#8217; Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239; </FONT>The
Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to <U>Section 7(d)</U> above
were to be determined by pro rata allocation or by any other method of allocation which does not take into account the equitable
considerations referred to <U>Section 7(d)</U> above. The amount paid or payable by an indemnified party as a result of the loss,
claim, damage, expense, liability, action, investigation or proceeding referred to in <U>Section 7(d)</U> above shall be deemed to
include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating, preparing to defend or defending against or appearing as a third party witness in respect of, or
otherwise incurred in connection with, any such loss, claim, damage, expense, liability, action, investigation or proceeding.
Notwithstanding the provisions of this <U>Section 7</U>, no Underwriter shall be required to contribute any amount in excess of the
amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the
Stock exceeds the amount of any damages which the Underwriter has otherwise paid or become liable to pay by reason of any untrue or
alleged untrue statement, omission or alleged omission, act or alleged act or failure to act or alleged failure to act. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution
from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations to contribute as
provided in this <U>Section 7</U> are several in proportion to their respective underwriting obligations and not joint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>8.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Termination</I>.</FONT> This Agreement may be terminated by
the Representative by notice to the Company (a) at any time prior to the Closing Date or the Option Closing Date (if different from the
Closing Date and then only as to the Optional Stock) if, prior to the applicable date, any of the events described in <U>Section 6(i)</U>,
<U>6(j)</U> or <U>6(k)</U> shall have occurred, or (b) as provided in&nbsp;<U>Section 10</U>&nbsp;of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>9.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Reimbursement of Underwriters&#8217; Expenses</I></FONT>. Notwithstanding
anything to the contrary in this Agreement, if (a) this Agreement shall have been terminated pursuant to <U>Section 8</U> or <U>10</U>,
(b) the Company shall fail to tender the Stock for delivery to the Underwriters for any reason not permitted under this Agreement, (c)
the Underwriters shall decline to purchase the Stock for any reason permitted under this Agreement or (d) the sale of the Stock is not
consummated because any condition to the obligations of the Underwriters set forth herein is not satisfied or because of the refusal,
inability or failure on the part of the Company to perform any agreement herein or to satisfy any condition or to comply with the provisions
hereof, then in addition to the payment of amounts in accordance with <U>Section 5</U>, the Company shall reimburse the Underwriters for
the reasonable and documented fees and expenses of Underwriters&#8217; counsel and for such other out-of-pocket expenses as shall have
been actually and reasonably incurred by them in connection with this Agreement and the proposed purchase of the Stock, and upon demand
the Company shall pay the full amount thereof to the Representative; <U>provided</U> that if this Agreement is terminated pursuant to
<U>Section 10</U> by reason of the default of one or more Underwriters, the Company shall not be obligated to reimburse any defaulting
Underwriter on account of expenses to the extent incurred by such defaulting Underwriter, <U>provided further</U> that the foregoing shall
not limit any reimbursement obligation of the Company to any non-defaulting Underwriter under this <U>Section 9</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>10.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Substitution of Underwriters</I></FONT>. If any Underwriter
or Underwriters shall default in its or their obligations to purchase shares of Stock hereunder on any Closing Date and the aggregate
number of shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed ten percent (10%) of
the total number of shares to be purchased by all Underwriters on such Closing Date, the other Underwriters shall be obligated severally,
in proportion to their respective commitments hereunder, to purchase the shares which such defaulting Underwriter or Underwriters agreed
but failed to purchase on such Closing Date. If any Underwriter or Underwriters shall so default and the aggregate number of shares with
respect to which such default or defaults occur is more than ten percent (10%) of the total number of shares to be purchased by all Underwriters
on such Closing Date and arrangements satisfactory to the Representative and the Company for the purchase of such shares by other persons
are not made within forty&#45;eight (48) hours after such default, this Agreement shall terminate.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the remaining
Underwriters or substituted Underwriters are required hereby or agree to take up all or part of the shares of Stock of a defaulting
Underwriter or Underwriters on such Closing Date as provided in this <U>Section&nbsp;10</U>, (i) the Company shall have the right to
postpone such Closing Date for a period of not more than five (5) full business days in order that the Company may effect whatever
changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements,
and the Company agrees promptly to file any amendments to the Registration Statement or supplements to the Prospectus which may
thereby be made necessary, and (ii) the respective numbers of shares to be purchased by the remaining Underwriters or substituted
Underwriters shall be taken as the basis of their underwriting obligation for all purposes of this Agreement. Nothing herein
contained shall relieve any defaulting Underwriter of its liability to the Company or the other Underwriters for damages occasioned
by its default hereunder. Any termination of this Agreement pursuant to this <U>Section 10</U> shall be without liability on the
part of any non&#45;defaulting Underwriter or the Company, except that the representations, warranties, covenants, indemnities,
agreements and other statements set forth in <U>Section 2</U>, the obligations with respect to expenses to be paid or reimbursed
pursuant to <U>Sections 5</U> and <U>9</U> and the provisions of <U>Section 7</U> and <U>Sections 11</U> through <U>22</U>,
inclusive, shall not terminate and shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>11.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Absence of Fiduciary Relationship. </I></FONT>The Company acknowledges
and agrees that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(a) &#8239;&#8239;&#8239;&#8239;each
Underwriter&#8217;s responsibility to the Company is solely contractual in nature, the Representative have been retained solely to act
as underwriters in connection with the sale of the Stock and no fiduciary, advisory or agency relationship between the Company and the
Representative have been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Representative
has advised or is advising the Company on other matters;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(b) &#8239;&#8239;&#8239;&#8239;the
price of the Stock set forth in this Agreement was established by the Company following discussions and arms-length negotiations with
the Representative, and the Company is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions
of the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(c) &#8239;&#8239;&#8239;&#8239;&#8239;it
has been advised that the Representative and its affiliates are engaged in a broad range of transactions which may involve interests that
differ from those of the Company and that the Representative has no obligation to disclose such interests and transactions to the Company
by virtue of any fiduciary, advisory or agency relationship; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(d) &#8239;&#8239;&#8239;&#8239;&#8239;it
waives, to the fullest extent permitted by law, any claims it may have against the Representative for breach of fiduciary duty or alleged
breach of fiduciary duty and agrees that the Representative shall have no liability (whether direct or indirect) to the Company in respect
of such a fiduciary duty claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders,
employees or creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>12.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Successors; Persons Entitled to Benefit of Agreement</I></FONT>.
This Agreement shall inure to the benefit of and be binding upon the several Underwriters, the Company, and their respective successors
and assigns. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, other than the persons
mentioned in the preceding sentence, any legal or equitable right, remedy or claim under or in respect of this Agreement, or any provisions
herein contained, this Agreement and all conditions and provisions hereof being intended to be and being for the sole and exclusive benefit
of such persons and for the benefit of no other person; except that the representations, warranties, covenants, agreements and indemnities
of the Company, contained in this Agreement shall also be for the benefit of the Underwriter Indemnified Parties, and the indemnities
of the several Underwriters shall be for the benefit of the Company Indemnified Parties. It is understood that each Underwriter&#8217;s
responsibility to the Company is solely contractual in nature and the Underwriters do not owe the Company, or any other party, any fiduciary
duty as a result of this Agreement. No purchaser of any of the Stock from any Underwriter shall be deemed to be a successor or assign
by reason merely of such purchase.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>13.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Survival of Indemnities, Representations, Warranties, etc</I></FONT><I>.
</I>The respective indemnities, covenants, agreements, representations, warranties and other statements of the Company, and the several
Underwriters, as set forth in this Agreement or made by them respectively, pursuant to this Agreement, shall remain in full force
and effect, regardless of any investigation made by or on behalf of any Underwriter, the Company or any person controlling any of them
and shall survive delivery of and payment for the Stock. Notwithstanding any termination of this Agreement, including without limitation
any termination pursuant to <U>Section 8</U> or <U>Section 10</U>, the indemnities, covenants, agreements, representations, warranties
and other statements forth in <U>Sections 2</U>, <U>5</U>, <U>7</U> and <U>9</U> and <U>Sections 11</U> through <U>22</U>, inclusive,
of this Agreement shall not terminate and shall remain in full force and effect at all times.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-variant: small-caps"><I>14.</I></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Recognition of the U.S. Special Resolution Regimes.</I></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT> In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime,
the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to
the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and
obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT>In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding
under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted
to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement
were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>15.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Notices</I></FONT>. All statements, requests, notices and agreements
hereunder shall be in writing, and:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT>if to the Underwriters, shall be delivered or sent by mail, telex, facsimile transmission or email to Lake Street Capital Markets,
LLC, Attention: Michael Townley, CEO and Head of Investment Banking, mike.townley@lakestreetcm.com; with a copy to Nelson Mullins Riley
 &amp; Scarborough LLP, 101 Constitution Avenue, NW, Suite 900, Washington, DC 20001, Attention: Jonathan H. Talcott, jon.talcott@nelsonmullins.com
and Michael K. Bradshaw, Jr., mike.bradshaw@nelsonmullins.com; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;
</FONT>if to the Company, shall be delivered or sent by mail, telex, facsimile transmission or email to ClearPoint Neuro, Inc., Attention:
General Counsel, 120 S. Sierra Avenue, Suite 100, Solana Beach, California 92075; with a copy to Bass Berry &amp; Sims PLC, 100 Peabody
Place, Suite 1300, Memphis, TN 38103, Attention: Richard F. Mattern, rmattern@bassberry.com;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>provided</U>, <U>however</U><I>,</I>
that any notice to an Underwriter pursuant to <U>Section 7</U> shall be delivered or sent by mail, or facsimile transmission to such Underwriter
at its address set forth in its acceptance telex to the Representative, which address will be supplied to any other party hereto by the
Representative upon request. Any such statements, requests, notices or agreements shall take effect at the time of receipt thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>16.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Definition of Certain Terms</I></FONT>. For purposes of
                                                                        this Agreement, (a) &#8220;<B><I>affiliate</I></B>&#8221; has the meaning set forth in Rule 405 under the Securities Act, (b)
                                                                        &#8220;<B><I>business day</I></B>&#8221; means any day on which the New York Stock Exchange, Inc. is open for trading, (c)
                                                                        &#8220;<B><I>subsidiary</I></B>&#8221; has the meaning set forth in Rule&nbsp;405 of the Rules and Regulations, (d) &#8220;<B><I>BHC
                                                                        Act Affiliate</I></B>&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance
                                                                        with, 12 U.S.C. &sect; 1841(k), (e) &#8220;<B><I>Covered Entity</I></B>&#8221; means any of the following: (i) a &#8220;covered
                                                                        entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;252.82(b); (ii) a &#8220;covered
                                                                        bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;47.3(b); or (iii) a &#8220;covered
                                                                        FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &sect;&nbsp;382.2(b), (f) &#8220;<B><I>Default
                                                                        Right</I></B>&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect;
                                                                        252.81, 47.2 or 382.1, as applicable, and (g) &#8220;<B><I>U.S. Special Resolution Regime</I></B>&#8221; means each of (i) the
                                                                        Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer
Protection Act and the regulations promulgated thereunder.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>17.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Governing Law, Jurisdiction, Waiver of Jury Trial.</I></FONT>
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, including without limitation Section
5-1401 of the New York General Obligations Law. The Company irrevocably (a) submits to the exclusive jurisdiction of the Federal and state
courts in the Borough of Manhattan in The City of New York for the purpose of any suit, action or other proceeding arising out of this
Agreement or the transactions contemplated by this Agreement, the Registration Statement and any Preliminary Prospectus or the Prospectus,
(b) agrees that all claims in respect of any such suit, action or proceeding may be heard and determined by any such court, (c) waives
to the fullest extent permitted by applicable law, any immunity from the jurisdiction of any such court or from any legal process, (d)
agrees not to commence any such suit, action or proceeding other than in such courts, and (e) waives, to the fullest extent permitted
by applicable law, any claim that any such suit, action or proceeding is brought in an inconvenient forum. <B>Each of the parties to this
Agreement hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>18.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Underwriters&#8217; Information</I></FONT><I>.</I> The parties
hereto acknowledge and agree that, for all purposes of this Agreement, the &#8220;<B><I>Underwriters&#8217; Information</I></B>&#8221;
consists solely of the following information in the Prospectus: (i) the last paragraph on the front cover page concerning the terms of
the offering by the Underwriters; and (ii) the statements concerning the Underwriters contained in the eighth, tenth, eleventh, twelfth,
and thirteenth paragraphs under the heading &#8220;Underwriting.&#8221;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>19.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Authority of the Representative</I></FONT>. In connection with
this Agreement, the Representative will act for and on behalf of the several Underwriters, and any action taken under this Agreement by
the Representative, will be binding on all the Underwriters.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>20.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Partial Unenforceability</I>. </FONT>The invalidity or unenforceability
of any section, paragraph, clause or provision of this Agreement shall not affect the validity or enforceability of any other section,
paragraph, clause or provision hereof. If any section, paragraph, clause or provision of this Agreement is for any reason determined to
be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make
it valid and enforceable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>21.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>General</I></FONT>. This Agreement constitutes the entire agreement
of the parties to this Agreement and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and
negotiations with respect to the subject matter hereof. In this Agreement, the masculine, feminine and neuter genders and the singular
and the plural include one another. The section headings in this Agreement are for the convenience of the parties only and will not affect
the construction or interpretation of this Agreement. This Agreement may be amended or modified, and the observance of any term of this
Agreement may be waived, only by a writing signed by the Company and the Representative.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><I>22.</I></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><I>Counterparts</I></FONT>. This Agreement may be signed in any
number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument. This Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered
shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[<I>Signature
page follows</I>]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; color: red"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; color: red">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the foregoing is in accordance
with your understanding please indicate your acceptance of this Agreement by signing in the space provided for that purpose below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: justify">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps">ClearPoint
    Neuro, Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">/s/ Joseph M. Burnett</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 3%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 5%">Name:</TD>
  <TD STYLE="text-align: justify">Joseph M. Burnett</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">&nbsp;</TD>
  <TD STYLE="text-align: justify">Title:</TD>
  <TD STYLE="text-align: justify">President and Chief Executive Officer</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Accepted as of the date first above written: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">Lake
Street Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="text-indent: -0.25in; margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"></FONT> Acting on its own behalf<BR> and as Representative of the several<BR> Underwriters listed on <U>Schedule
A</U> to this Agreement. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 3%">By: </TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Michael Townley</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 5%">Name: </TD>
  <TD STYLE="width: 45%">Michael Townley</TD>
  <TD STYLE="width: 50%">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
  <TD>Title: </TD>
  <TD>CEO and Head of Investment Banking &nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature Page to Underwriting
Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Name</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares of <BR> Firm Stock to be <BR> Purchased</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares of <BR> Optional Stock to be <BR> Purchased</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Lake Street Capital Markets, LLC</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">2,307,694</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">346,154</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; font-size: 10pt; text-align: justify">Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,307,694</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">346,154</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center"><B>SCHEDULE B</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">General Use Free Writing Prospectuses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 1.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE C</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pricing Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Firm Stock to be Sold: 2,307,694 shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Optional Stock: 346,154 shares</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Offering Price to Public: $6.50 per share</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Underwriting Discounts and Commissions: 5.0% (excluding
commissions on Excluded Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Estimated Net Proceeds to the Company (after underwriting
discounts and commissions, but before transaction expenses): $14.3 million</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Trade Date: February 29, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Closing Date: March 4, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-align: left"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red; text-align: left">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE D</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Joseph M. Burnett</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">R. John Fletcher</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Lynnette C. Fallon</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Pascal E.R. Girin</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">B. Kristine Johnson</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Matthew B. Klein</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Linda M. Liau</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Timothy T. Richards</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Danilo D&#8217;Alessandro</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Mazin Sabra</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: windowtext">Jeremy L. Stigall</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE E</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">ClearPoint Neuro Germany GmbH</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">ClearPoint Neuro Italy, S.r.l.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">ClearPoint Neuro (Canada) Inc.</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">ClearPoint Neuro UK Ltd.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Lock&#45;Up Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Form of Lock&#45;Up Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">________, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-variant: small-caps">Lake Street
Capital Markets, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt; text-align: justify">As Representative of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">920 Second Avenue South, Suite 700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Minneapolis, Minnesota 55402</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Re: ClearPoint Neuro, Inc.
 &#8212; Restriction on Stock Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs and Madams:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This letter agreement (this
 &#8220;<B><I>Agreement</I></B>&#8221;) is being delivered to you in connection with the proposed Underwriting Agreement (the &#8220;<B><I>Underwriting
Agreement</I></B>&#8221;) by and between ClearPoint Neuro, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;) and
Lake Street Capital Markets, LLC, as representative (the &#8220;<B><I>Representative</I></B>&#8221;) of a group of underwriters (collectively,
the &#8220;<B><I>Underwriters</I></B>&#8221;), to be named therein, and the other parties thereto (if any), relating to the proposed public
offering (the &#8220;<B><I>Offering</I></B>&#8221;) of shares of the common stock, par value $0.01 per share (the &#8220;<B><I>Common
Stock</I></B>&#8221;), of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to induce the Underwriters
to enter into the Underwriting Agreement, and in light of the benefits that the Offering will confer upon the undersigned in his, her
or its capacity as a securityholder and/or an officer, director or employee of the Company, and for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each Underwriter that, during the period beginning
on the date hereof through and including the date that is the 90th day after the date of the Underwriting Agreement (the &#8220;<B><I>Lock-Up
Period</I></B>&#8221;), the undersigned will not, and will not cause or direct any of its affiliates to, without the prior written consent
of the Representative, directly or indirectly, (i) offer, sell, assign, transfer, pledge, contract to sell, lend or otherwise dispose
of, or announce the intention to otherwise dispose of, (A) any shares of Common Stock (including, without limitation, Common Stock which
may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations promulgated under the Securities
Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;), as the same may be amended or supplemented from time to time
(such shares, the &#8220;<B><I>Beneficially Owned Shares</I></B>&#8221;)), or (B) securities convertible into or exercisable or exchangeable
for Common Stock, (ii) enter into, or announce the intention to enter into, any swap, hedge or similar agreement or arrangement (including,
without limitation, the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other
derivative transaction or instrument, however described or defined) that transfers, is designed to transfer or reasonably could be expected
to transfer (whether by the undersigned or someone other than the undersigned) in whole or in part, directly or indirectly, the economic
risk of ownership of the Beneficially Owned Shares or securities convertible into or exercisable or exchangeable for Common Stock, whether
now owned or hereafter acquired by the undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition
(the &#8220;<B><I>Prohibited Activity</I></B>&#8221;), or (iii) engage in, or announce the intention to engage in, any short selling of
the Common Stock or securities convertible into or exercisable or exchangeable for Common Stock. The undersigned represents and warrants
that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement
or arrangement that is designed to or which reasonably could be expected to lead to or result in any Prohibited Activity during the Lock-Up
Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The restrictions set forth
in the immediately preceding paragraph shall not apply to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239; </FONT>if
the undersigned is a natural person, any transfers made by the undersigned (a)&nbsp;as a bona fide gift to any member of the
immediate family (as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or
members of the undersigned&#8217;s immediate family, (b)&nbsp;by will or intestate succession upon the death of the undersigned or
(c)&nbsp;as a bona fide gift to a charity or educational institution;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfers to any stockholder,
partner or member of, or owner of a similar equity interest in, the undersigned, as the case may be, if, in any such case, such transfer
is not for value;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>if the undersigned is a corporation, partnership, limited liability company or other business entity, any transfer made by the
undersigned (a) in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&#8217;s
capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
all of the undersigned&#8217;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement
or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate
(as defined below) of the undersigned and such transfer is not for value;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>transactions relating to Common Stock or other securities convertible into or exercisable or exchangeable for Common Stock acquired
in open market transactions after completion of the Offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>the conversion or exchange of securities convertible into or exercisable or exchangeable for Common Stock outstanding as of the
date of this agreement, it being understood that any Common Stock issued upon such exchanges or conversions will be subject to the restrictions
of this agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT><FONT STYLE="background-color: white">the grant, exercise or settlement of any stock options and equity awards pursuant to the
Company&#8217;s equity incentive plans, and the related issuances of Common Stock with respect to such stock options and equity awards;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>sales of Common Stock made pursuant to and in accordance with a trading plan pursuant to Rule 10b5-1 under the Securities Exchange
Act of 1934, as amended (the &#8220;<B><I>Exchange Act</I></B>&#8221;), existing on the date hereof; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(8)<FONT STYLE="font-family: Times New Roman, Times, Serif">&#8239;&#8239;&#8239;&#8239;&#8239;
</FONT>any transfers made by the undersigned to the Company to satisfy tax withholding obligations pursuant to the Company&#8217;s equity
incentive plans or arrangements disclosed in the Prospectus (as defined in the Underwriting Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>provided</U>, <U>however</U>, that in the
case of any transfer described in clause&nbsp;(1), (2) or (3)&nbsp;above, it shall be a condition to the transfer that (A)&nbsp;the
transferee executes and delivers to the Representative, acting on behalf of the Underwriters, not later than one business day prior
to such transfer, a written agreement, in substantially the form of this Agreement (it being understood that any references to
 &#8220;immediate family&#8221; in the agreement executed by such transferee shall expressly refer only to the immediate family of
the undersigned and not to the immediate family of the transferee) and otherwise satisfactory in form and substance to the
Representative, and (B) in the case of any transfer or transaction described above, no public announcement or filing is voluntarily
made regarding such transfer during the Lock-Up Period and if the undersigned is required to file a report under Section&nbsp;16(a)
of the Exchange Act, reporting a reduction in beneficial ownership of shares of Common Stock or Beneficially Owned Shares or any
securities convertible into or exercisable or exchangeable for Common Stock or Beneficially Owned Shares during the Lock-Up Period,
the undersigned shall include a statement in such report to the effect that, (A) in the case of any transfer pursuant to
clause&nbsp;(1) above, such transfer is being made as a gift or by will or intestate succession, (B) in the case of any transfer
pursuant to clause&nbsp;(2) above, such transfer is being made to a stockholder, partner or member of, or owner of a similar equity
interest in, the undersigned and is not a transfer for value, (C) in the case of any transfer pursuant to clause (3) above, such
transfer is being made either (a) in connection with the sale or other bona fide transfer in a single transaction of all or
substantially all of the undersigned&#8217;s capital stock, partnership interests, membership interests or other similar equity
interests, as the case may be, or all or substantially all of the undersigned&#8217;s assets or (b) to another corporation,
partnership, limited liability company or other business entity that is an affiliate of the undersigned and such transfer is not for
value, and (D) in the case of any transfer pursuant to clause (8) above, such transfer is being made to satisfy tax withholding
obligations. For purposes of this paragraph, &#8220;immediate family&#8221; shall mean a spouse, child, grandchild or other lineal
descendant (including by adoption), father, mother, brother or sister of the undersigned; and &#8220;affiliate&#8221; shall have the
meaning set forth in Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to enable this covenant
to be enforced, the undersigned hereby consents to the placing of legends or stop transfer instructions with the Company&#8217;s transfer
agent with respect to any Common Stock or securities convertible into or exercisable or exchangeable for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned further agrees
that it will not, during the Lock-Up Period, make any demand or request for or exercise any right with respect to the registration under
the Securities Act, of any shares of Common Stock or other Beneficially Owned Shares or any securities convertible into or exercisable
or exchangeable for Common Stock or other Beneficially Owned Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this Agreement and that this Agreement has been duly authorized
(if the undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned.
This Agreement and all authority herein conferred are irrevocable and shall survive the death or incapacity of the undersigned (if a natural
person) and shall be binding upon the heirs, personal representatives, successors and assigns of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall be governed
by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such
state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If (i) the Company notifies
the Representative in writing that it does not intend to proceed with the Offering or (ii) the Underwriting Agreement (other than the
provisions thereof which survive termination) shall terminate or be terminated for any reason prior to payment for and delivery of any
Common Stock to be sold thereunder, then this Agreement shall immediately be terminated and the undersigned shall automatically be released
from all of his, her or its obligations under this Agreement. The undersigned acknowledges and agrees that whether or not any public offering
of Common Stock actually occurs depends on a number of factors, including market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature page follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: left">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD COLSPAN="3" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">(Name of Stockholder - Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">(Signature)</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">(Name of Signatory if Stockholder is an
entity - Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">(Title of Signatory if Stockholder is
an entity - Please Print)</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 3%">&nbsp;</TD>
  <TD STYLE="text-align: left; width: 8%">Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 39%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="text-align: left">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>Signature
Page to Lock-Up Agreement</I></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 41; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm247180d4_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="tm247180d4_ex5-1img001.jpg" ALT="" STYLE="height: 24px; width: 225px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Tower at Peabody Place</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">100 Peabody Place, Suite&nbsp;1300<BR>
Memphis, Tennessee 38103</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(901) 543-5900</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">March&nbsp;1, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ClearPoint Neuro,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">120 S. Sierra Ave., Suite&nbsp;100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Solana Beach, CA 92075</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 10pt">We
have acted as counsel to ClearPoint Neuro,&nbsp;Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection
with a Registration Statement on Form&nbsp;S-3, Registration No.&nbsp;333-275476 (the &#8220;<B><I>Registration Statement</I></B>&#8221;),
filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;<B><I>Commission</I></B>&#8221;) pursuant to the Securities
Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;), and the related Prospectus Supplement filed with the Commission
on March&nbsp;1, 2024 (the &#8220;<B><I>Prospectus Supplement</I></B>&#8221;), relating to (i)&nbsp;the sale by the Company of 2,307,694
shares (the &#8220;<B><I>Firm Shares</I></B>&#8221;) of the Company&#8217;s common stock, par value $0.01 per share (&#8220;<B><I>Common
Stock</I></B>&#8221;), and (ii)&nbsp;the sale by the Company, at the option of the Underwriter (as defined below), of up to 346,154 additional
shares of Common Stock </FONT>solely to cover over-allotments (the &#8220;<B><I>Optional Shares</I></B>,&#8221; and, together with the
Firm Shares, the &#8220;<B><I>Shares</I></B>&#8221;), being offered by the Company pursuant to the Underwriting Agreement, dated February&nbsp;28,
2024 (the &#8220;<B><I>Underwriting Agreement</I></B>&#8221;), by and between the Company and Lake Street Capital Markets, LLC (the &#8220;<B><I>Underwriter</I></B>&#8221;).
This opinion is being furnished in connection with the requirements of Item&nbsp;601(b)(5)&nbsp;of Regulation S-K under the Securities
Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or the Prospectus Supplement,
other than as expressly stated herein with respect to the issuance of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 10pt">In
connection with this opinion, we have examined and relied upon the Registration Statement and the Prospectus Supplement, the Underwriting
Agreement, the Company&#8217;s Amended and Restated Certificate of Incorporation, as amended from time to time, the Company&#8217;s Fourth
Amended and Restated Bylaws, that certain Opinion Certificate dated as of the date hereof and delivered by </FONT>Danilo D&#8217;Alessandro,
Chief Financial Officer of the Company, and originals or copies certified to our satisfaction of such other records, documents, certificates,
memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinions expressed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
our aforesaid examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the accuracy and
completeness of all documents submitted to us, the authenticity of all original documents, and the conformity to authentic original documents
of all documents submitted to us as certified, telecopied, photostatic, or reproduced copies. We have also assumed the accuracy, completeness
and authenticity of the foregoing certifications of officers and statements of fact, on which we are relying, and have made no independent
investigations thereof. This opinion letter is given, and all statements herein are made, in the context of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Based
upon and subject to the foregoing and the other assumptions and qualifications set forth herein, it is our opinion that, as of the date
hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The</FONT> Firm Shares have been duly authorized and, when issued and delivered
by the Company against payment of the consideration set forth in the Underwriting Agreement, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The Optional Shares have been duly authorized, and assuming the due and proper exercise of the Underwriter&#8217;s
option in accordance with the terms of the Underwriting Agreement and, when issued and delivered by the Company pursuant to the Underwriting
Agreement against payment of the consideration set forth therein, will be validly issued, fully paid and non-assessable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
opinion also is subject to the following qualifications:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Our opinions as set forth herein are limited in all respects to the federal laws of the United States
of America and, to the extent applicable, the General Corporation Law of the State of Delaware. No opinion is given regarding the laws
of any other jurisdiction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">We express no opinion with respect to the registration or qualification of the Securities under any state
securities or &#8220;Blue Sky&#8221; laws.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">This letter is strictly limited to those matters expressly addressed herein. We express no opinion as
to any matter not specifically stated to be and numbered above as an opinion.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">This letter is rendered as of the date hereof and we assume no responsibility to update this letter for
any changes in applicable law occurring after the date hereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Securities Act. We consent to your filing this opinion as an exhibit to the Company&#8217;s
Current Report on Form&nbsp;8-K, to be filed March&nbsp;1, 2024. In giving such consent, we do not thereby admit that we are in the category
of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD>
  <TD>/s/ Bass, Berry&nbsp;&amp; Sims, PLC</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 3in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 3in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm247180d4_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm247180d4_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  8 .$# 2(  A$! Q$!_\0
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F071Y\Q(@"/IZ?A6A)8VTK;GA0MG.<8.>.?T%%% $^!1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>clpt-20240228.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaWIubOdzZR+uYkxtmBwbTnKjysoOJdGHiRPfQkWAb4G -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:clpt="http://clearpointneuro.com/20240228" elementFormDefault="qualified" targetNamespace="http://clearpointneuro.com/20240228">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://clearpointneuro.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="clpt-20240228_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="clpt-20240228_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>clpt-20240228_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>clpt-20240228_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.21b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://clearpointneuro.com/role/Cover" xlink:href="clpt-20240228.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://clearpointneuro.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139755267797072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 28,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CLEARPOINT NEURO, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001285550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2394628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">120 S. Sierra Ave., Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Solana Beach<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">287-9109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CLPT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB8Q6A8#BJ?H'LHG6.9 U 3;(-@)618#B&7LA#!R&Y(KX]-?E;V3.PQSBK;;
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MLX!A6#A("E+N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ LX!A6)E<G",0!@  G"<  !,
M ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "S@&%8J)?Q
MM58$  "+$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ LX!A6)^@&_"Q @  X@P   T
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;72YX;6Q02P4&      D "0 ^ @  [1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm247180d4_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://clearpointneuro.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>clpt-20240228.xsd</File>
    <File>clpt-20240228_lab.xml</File>
    <File>clpt-20240228_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm247180d4_8k.htm">tm247180d4_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm247180d4_8k.htm": {
   "nsprefix": "clpt",
   "nsuri": "http://clearpointneuro.com/20240228",
   "dts": {
    "schema": {
     "local": [
      "clpt-20240228.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "clpt-20240228_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clpt-20240228_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm247180d4_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://clearpointneuro.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-02-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm247180d4_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-02-28",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm247180d4_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://clearpointneuro.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001104659-24-029960-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-029960-xbrl.zip
M4$L#!!0    ( +. 85A7_YZ@+P,  /@+   1    8VQP="TR,#(T,#(R."YX
M<V2U5MMRTS 0?6>&?Q!^[=B.$PIMFK13VFD)I+0DO=$71K8WJ:@L&4EN4KX>
MR9?<G)@D@)_DU3EG=[6[LEM'XXBB9Q"2<-:V/*=F(6 !#PD;MJV;OGW</^ET
M+'1T^/H5TD_KC6VC,P(T;*)3'M@=-N 'Z N.H(G.@8' BHL#=(MI8BS\C% 0
MZ(1',04%>B/SU$2[3MWSD6VOH7L++.3BIM>9Z#XJ%<NFZXY&(X?Q9SSBXDDZ
M 8_6$^PKK!(Y4:N-:_FS'OV"R&!"WL''NZ/WXQZY'P+;2[JX\1#<X;M.XE^&
MOQYZ.\FWI[&*/HS\:_;YQXODEY_"\X^D=S7X^G1W[+\]SURV9/ ($4:Z&$RV
M+9-?GMZHX7 Q=.NUFN?>7W3[*<[*@,TQ)>QI&=S;W]]WT]T"6D*.?4$+Z89K
MMGTL8:*L=TD%GC"I, OF\*&:$&;!NVZV.0<E2Z'O,B@IH"$LX"0$SI _NWI#
MX^N- IA(>XAQ/ $/L/13T7QC#BR%*@.U<1%DJY<8Y%)HMC5'"&@\E0TH8!%S
MPA2#1'#3F@;\ME:O[^D!HQ !4V=<1*<PP G5Q)\)IF1 (+20PF((RO2:C'$
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MH<?P31&@.#0^J&\4 F.H"--%YTC7C3W@WE9;?.-^N3>RVB/_ U!+ P04
M" "S@&%8A4,.(ZH4  !R;@  $0   '1M,C0W,3@P9#1?.&LN:'1M[3UK5]LX
MT]_S*_3FV0N<0RYV+H1 \YPT0)<MMX=+=[=?.(JM)"J.[4HV)/OKWQG)3NS$
M#H%"2W>[9PN))<V,1G.79/;^.QD[Y(X)R3WWS:]&N?HK8:[EV=P=OOFU>]D[
M.OKUOYW"WBB ;M#5E6^*HR#PVY7*_?U]^;Y6]L2P8NSL[%0FV*>H.[4GF?W,
M:M6H_'ER?&F-V)B6N"L#ZEIL-LCA[FT^?&R==>T+AZ>ZXI,82:VR!!I:[?F
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MSEQ*LK!6DK-%&L#D,0%.F$G5CH:U+97'!%J(<H/MD;*:J'2E6$7*$VD7H^8
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M'2_U@>$!!0+'%;HVUO@\T<;J1L"*G3.7Q!>*-'%F:ZN @<06Z>&[:,[Q731
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M58*DU7^;HH)_+TC].:I@['3^'U!+ P04    " "S@&%8:Y=EO3"P  #)]P,
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ME<9%7H%>=4$,C@J^+B32 <[(&6XVQ-2TT%H"=^U/$!%$:SC8("SM1$[SU-B
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M2T_H92N)&0ZN)<KV;:3EU@D_N<98^C,TD;/Q2OW?-YK_U.2M..(?3L-R=G9
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MSKFS^#L)7(B5SOZD8Q-K949\;EIZRS:@X'5G=4QB.+#7I"WTA*K$?EBB+4+
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MF,]KZ1G^)_3Q5]>+Y?H_"^!]Q@!>Z;1Y2:\]8PAQLZR8TGH6!*X8<#QOUX'
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M_EL!^CW3'QVJE\;SWWBE?G9]Y7,O0;GE%>( ,'M)7-0=5-QK.3[!EL:"490
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M>6Z@/IYVGF#N9,007\? 3<&.]>$3NK:SN$!/6OA%#O-54S.C[8V(X4#*<'$
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MR[(W(%1MC@T"J9LICTV;;;)GA?=7=-$R*9.3,EF>1CL</!BG7,*/BV]*[HC
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MY]/51 X =F=MCR?W,^Y/0PH%WU>P+%<P[3J#A.&#::GLG+@*'_A DC;1!(G
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M?7MT^.9II'3?Y/YHA@0&0%@$O726Y6P[:VH.WB1V"<3Z8NG(*C+B_)+8O02
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MB## TS^FH,EPTBXF8S!M>)/YYM3&KVDTDFRJ\R#V\6U4>5^DD8ULI5^U9TZ
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M7W_ADCB6@FC_E_.4RZJ ,W&6+O7KV<@:L"@LFV!FP*7WG>\G;KZ8P/A'MGW
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M]Y10S07>;._)P0')1053V"4L\RWL8=ZEJZ0VH'!=S,.ZG<.1(<TB>@Y,*VJ
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M[-49P> M+\W(;[-1KRU<@DNX;:/U>VW-_E_.;;MLINRUC18[4W4\YLK>5)6
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M?ZPJ8V%@7%A,9ZQ*U>#M)#:H/H]<SJHRGQRZ7I)0TW)1Z!C4$8Q9S5F11L=
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M6(^LY#':LSQ&[Y*ZN3TM(Y9[2OJWXZ\O?GOU;Z*H7S[]^NZG_P]02P,$%
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M]A1)^V]71UR"!K>!N,*NP^:"F4)#W/' 4!FA"?0O\6L:1^%#6,BS5CD8MH@
M<%TQ01G=][+\27)O1 :9<R!53J2+"Q,R8:&L6<NZ$Q4%3,/;!E'XMUS)VRA5
M>@9;RI2=+5 [&58$_;LV1MA5%EA%2RR1\66TT+5!-ZY)H@</WN9,F3%\GX?2
MCU@_,Z7G(S3P+@JX:N5\)L6$O94A0D""G:XF4$198+*1E2 [4A(8XGY"P>AB
M)0$XU]H&?9@\9HB<IF4RX6Z>O9+4G3$;G4K A1YFZ45N:KC(R<?3W!*8$X@
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MBU6J)/YA$35OE>F#3'1V-%%0_%S>;I2W<"Z\RA;4\!FCRIA0_Z?\U/N!T\.
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M,#(T,#(R.%]L86(N>&UL4$L! A0#%     @ LX!A6-2V&?Q=!P  XU<  !4
M             ( !C@X  &-L<'0M,C R-# R,CA?<')E+GAM;%!+ 0(4 Q0
M   ( +. 85B%0PXCJA0  ')N   1              "  1X6  !T;3(T-S$X
M,&0T7SAK+FAT;5!+ 0(4 Q0    ( +. 85AKEV6],+   ,GW P 4
M      "  ?<J  !T;3(T-S$X,&0T7V5X,2TQ+FAT;5!+ 0(4 Q0    ( +.
M85BG!\%(L L  * S   4              "  5G;  !T;3(T-S$X,&0T7V5X
=-2TQ+FAT;5!+!08     !@ & (@!   [YP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tm247180d4_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="clpt-20240228.xsd" xlink:type="simple"/>
    <context id="AsOf2024-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001285550</identifier>
        </entity>
        <period>
            <startDate>2024-02-28</startDate>
            <endDate>2024-02-28</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-02-28" id="ixv-284">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-02-28" id="ixv-285">0001285550</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-02-28" id="ixv-305">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-02-28" id="ixv-306">2024-02-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-02-28" id="ixv-307">CLEARPOINT NEURO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-02-28" id="ixv-308">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-02-28" id="ixv-309">001-34822</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-02-28" id="ixv-310">58-2394628</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-02-28" id="ixv-311">120 S. Sierra Ave., Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-02-28" id="ixv-312">Solana Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-02-28" id="ixv-313">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-02-28" id="ixv-314">92075</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-02-28" id="ixv-315">888</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-02-28" id="ixv-316">287-9109</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-02-28" id="ixv-317">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-02-28" id="ixv-318">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-02-28" id="ixv-319">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-02-28" id="ixv-320">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-02-28" id="ixv-321">Common Stock, $0.01 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-02-28" id="ixv-322">CLPT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-02-28" id="ixv-323">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-02-28" id="ixv-324">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
